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Drug price reforms: the new F1–F2 bifurcation
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Significant	changes	to	the	Pharmaceutical	Benefits	Scheme	
(PBS)	are	underway.	The	Australian	Parliament	recently	passed	
the	National Health Amendment (Pharmaceutical Benefits 
Scheme) Act 2007.	At	the	core	of	this	Act	are	new	sections	
(85AB	and	85AC)	to	the	National Health Act 1953.	These	had	the	
effect	of	dividing,	from	1	August	2007,	the	PBS	into	two	separate	
formularies	–	F1,	which	mostly	contains	single	brand	medicines,	
and	F2,	which	mostly	contains	multiple	brand,	mainly	generic,	
medicines	(see	box).
These	complex	changes	aim	to	'recognise	the	importance	of	
world-class	life-enhancing	drugs	to	patients',	protect	patients	
from	higher	costs	and	get	better	value	from	market	competition	
between	medicines	with	multiple	brands.1	The	changes	may	
allow	PBS	and	patient	savings	through	lower	priced	generics,	
but	their	impact	on	the	price	of	patented	single-brand	medicines	
is	uncertain	in	our	view.	Chiefly	this	is	because	in	future	most	
new	patented	medicines	will	be	listed	in	F1	with	reduced	
reference	pricing	thereafter.
In	Australia,	overall	pharmacy	fees	vary	for	products	priced	
below	the	general	patient	co-payment	($30.70),	and	a	Choice	
survey	in	August	2006	found	a	wide	range	in	the	prices	
pharmacies	charge.2		This	was	due	to	varied	application	of	
permissible	fees	under	the	Fourth	Community	Pharmacy	
Agreement.	Australian	prices	for	generic	drugs	were	higher	
than	in	countries	with	larger	markets	or	processes	such	as	
competitive	tender.	In	Australia,	the	price	a	patient	paid	for	
a	medicine	below	the	general	co-payment	depended	on	the	
manufacturer's	price,	wholesale	and	pharmacy	markups,	and	
dispensing	fees.	Manufacturers	could	offer	generic	drugs	to	
pharmacists	at	large	discounts	to	the	prices	paid	by	the	PBS.	
The	government	therefore	considered	that	it	had	been	paying	
too	much	for	these	medicines.	In	our	view,	this	consideration	
unfortunately	outweighed	policy	concerns	about	the	importance	
of	maintaining	the	full	integrity	of	PBS	reference	pricing.1,3	
PBS	prices	will	now	be	influenced	by	which	formulary	a	drug	is	
in	(Table	1).	To	add	to	the	complexity,	the	criteria	do	not	apply	
to	single	brand	combination	products,	as	they	could	have	
components	in	different	formularies.	
Drugs	which	are	in	F2	are	categorised	according	to	the	size	
of	the	discounts	to	pharmacy	as	at	1	october	2006.	When	the	
discount	was	less	than	25%	the	drug	is	in	F2A.	Drugs	which	
were	heavily	discounted	by	more	than	25%	are	in	F2T.			The	
suppliers	of	drugs	in	these	categories	will	have	to	disclose	to	
the	Department	of	Health	and	Ageing	the	actual	price	at	which	
they	sell	a	brand	to	wholesalers	or	pharmacies.	This	requirement	
applies	to	new	brands	of	F2A	medicines	from	1	August	2007	and	
to	new	brands	of	F2T	medicines	from	1	January	2011.	The	aim	is	
to	ensure	that	the	PBS	price	is	based	on	the	actual	supplier	price	
to	wholesalers	or	pharmacy.	
A	price	reduction	of	12.5%	at	the	time	of	PBS	listing	of	the	
first	generic	brand	of	a	drug	has	been	required	since	2005,	
and	will	continue	to	apply.	From	1	August	2008,	there	will	be	
F1	contains	drugs	with	a	single	brand,	however	it	does	not	
contain	those	single	brand	drugs	that	are	interchangeable	
on	an	individual	patient	basis	with	drugs	that	have	multiple	
brands	or	single	brand	combination	items.
F2	contains	drugs	with	multiple	brands	and	those	single	
brand	drugs	that	are	interchangeable	at	the	individual	patient	
level	with	drugs	that	have	multiple	brands.
There	are	many	balances	in	medicine.	Debra	Kennedy	
writes	on	balancing	the	use	of	antipsychotic	drugs	during	
pregnancy	with	the	risk	of	congenital	abnormalities,	
while	Stephen	Reddel	describes	how	the	benefits	of	
immunosuppression	for	myasthenia	gravis	have	to	be	
balanced	against	the	adverse	effects.
Paul	Komesaroff	discusses	the	delicate	balance	between	
health	professionals	and	the	pharmaceutical	industry.	
Sometimes	this	balance	is	upset	and	can	result	in	promotional	
activity	breaching	the	Medicines	Australia	Code	of	Conduct.
Governments	have	to	balance	health	budgets	and	there	
have	been	recent	reforms	of	the	Pharmaceutical	Benefits	
Scheme.	Tom	Faunce	and	Hans	Lofgren	give	their	view	of	
the	changes.
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further	compulsory	price	reductions	for	F2	drugs:	a	drop	of	
2%	per	year	for	three	years	for	drugs	in	F2A,	and	a	one-off	
price	reduction	of	25%	for	drugs	in	F2T	(on	1	August	2008).	
There	are	no	mandatory	price	cuts	for	drugs	in	F1.	There	will	be	
compensation	for	wholesalers	and	pharmacists	for	the	loss	of	
income	from	statutory	F2	price	reductions.	For	example,	from	
1	August	2008	pharmacists	will	receive	$1.50	each	time	they	
dispense	a	substitutable	brand	that	costs	the	patient	no	more	
than	the	co-payment.
Many	generic	drugs	are	already	priced	below	the	general	
patient	co-payment,	and	the	price	reductions	to	drugs	in		
F2	are	expected	to	result	in	more	drugs	falling	under	the		
co-payment.	The	Pharmacy	Guild	of	Australia	estimates	that		
the	price	of	more	than	400	brands,	below	the	general	PBS		
co-payment,	will	fall.4	Complete	price	and	volume	data	will	not	
be	available	for	drugs	once	they	fall	below	the	general	PBS		
co-payment.	Although	the	Drug	Utilisation	Sub-Committee	
of	the	Pharmaceutical	Benefits	Advisory	Committee	(PBAC)	
receives	some	data,	prescriptions	for	these	drugs	do	not	appear	
in	official	statistics	of	PBS	expenditure.
The	Minister	for	Health	and	Ageing	has	stated	that	the	role	of	
the	PBAC,	in	assessing	cost-effectiveness	and	cost	minimisation	
and	then	advising	the	Minister	on	the	listing	of	drugs	on	the	
PBS,	is	not	affected	by	the	legislation.5		Yet	the	responsibilities	
of	the	PBAC	will	be	formally	extended	to	include	advice	to	the	
Minister	on	exemptions	from	mandatory	price	reductions.	It	
will	also	advise	on	whether	drugs	are	'interchangeable	on	an	
individual	patient	basis',	a	standard	more	uncertain	than	the	
previous,	more	evidence-based,	'equivalence'	tests	used	to	
determine	Therapeutic	Group	Premiums	for	reference	pricing.	
Drugs	appearing	'equivalent'	on	average	effects	measured	
in	clinical	trials,	for	example,	may	not	be	'interchangeable'	
for	an	individual	patient.3	For	example,	while	citalopram	
and	escitalopram	were	in	the	same	reference	pricing	group,	
escitalopram	was	initially	included	in	F1	and	citalopram	was		
in	F2T.6
The	principle	of	reference	pricing,	that	drugs	with	identical	or	
similar	clinical	outcomes	should	have	similar	prices,	is	integral	
to	the	architecture	of	the	PBS	and	the	respect	it	has	achieved	
internationally.	In	our	view,	the	separation	of	listed	drugs	into	
two	groups	(F1	and	F2),	however	this	is	implemented,	weakens	
the	role	and	fiscal	benefits	of	referencing	pricing	in	the	PBS.	
Although	there	will	be	reference	pricing	within	F1,	an	effect	of	
the	changes	is	to	insulate	high	priced	single	brand	(patented)	
F1	drugs	from	price	cuts	and	from	the	reference	pricing	that	
applied	under	previous	PBS	processes.3	once	a	new	drug	is	
listed	on	the	PBS	as	F1,	its	price	will	not	be	linked	to	the	price	of	
any	similar	drug	in	F2.	F1	drugs	are	not	interchangeable	at	the	
individual	patient	level	with	drugs	that	have	multiple	brands,	
so	the	manufacturers	may	be	able	to	retain	their	original	PBS	
price	until	the	listing	of	a	bioequivalent	brand	satisfies	the	new	
standards	for	a	shift	to	F2.	Reductions	in	F2	drug	prices	will	
not	affect	F1	prices,	even	where	the	therapeutic	effect	of	an	F2	
medicine	is	similar	though	not	necessarily	'interchangeable	at	
the	individual	patient	level'.	
It	is	our	opinion	that	the	creation	of	the	F1	category	will,	over	
time,	result	in	higher	prices	for	some	patented	drugs	than	
would	have	been	the	case	under	previous	PBS	arrangements.	
The	government's	rationale	for	this	change	appears	to	be	that	
failure	to	make	such	changes	could	result	in	large	'special	
patient	contributions'	or	the	withdrawal	of	single-source	
products	from	the	PBS.5	
The	government,	Medicines	Australia,	the	Consumers'	Health	
Forum	and	several	professional	groups	view	the	F1–F2	changes	
as	a	means	of	achieving	lower	prices	and	greater	transparency	
in	the	generics	market.6	However,	the	expectation	of	price	
reductions	flowing	to	consumers	is	premised	on	trust	in	effective	
competition	among	retail	pharmacies.	If	direct	benefits	to	
Table 1
Examples of drugs in the new Pharmaceutical benefits Scheme formularies	*
F1 F2A F2T
atorvastatin fluvastatin simvastatin
bisoprolol carvedilol metoprolol
cefuroxime cephazolin cephalexin
celecoxib ketoprofen naproxen
doxorubicin	(pegylated	liposomal) doxorubicin –
levobunolol betaxolol timolol
olanzapine clozapine –
reboxetine – citalopram,	fluvoxamine
salmeterol – salbutamol
ticarcillin	with	clavulanic	acid – amoxycillin	with	clavulanic	acid
zolmitriptan sumatriptan –
– oxazepam diazepam
*	 as	at	2007	Sep	11
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Letters
Letters,	which	may	not	necessarily	be	published	in	full,	should	be	restricted	to	not	more	than	250	words.	When	relevant,	comment	on	the	
letter	is	sought	from	the	author.	Due	to	production	schedules,	it	is	normally	not	possible	to	publish	letters	received	in	response	to	material	
appearing	in	a	particular	issue	earlier	than	the	second	or	third	subsequent	issue.
patients	from	lower	generic	medicines	prices	or	government	
support	for	an	Australian	generics	industry	had	been	the	primary	
policy	objectives,	then	more	broadly	framed	legislation	could	
have	included	pharmacy	rewards	for	meeting	generic	dispensing	
targets,	an	incentive	period	of	market	exclusivity	for	the	first	
generic	market	entrant,	and	financial	incentives	for	patients	who	
elect	to	be	dispensed	a	generic,	or	for	patients	whose	doctors	
are	prepared	to	prescribe	generic	drugs.	The	role	of	the	patented	
pharmaceutical	industry	in	promoting	and	framing	these	
changes	is	also	controversial7,	particularly	if	the	new	system	
allows	price	reductions	to	be	deferred	for	some	products.
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Managing chronic obstructive pulmonary disease
Editor,	–	I	wonder	why	alpha-1	antitrypsin	deficiency	was	not	
mentioned	in	the	article	on	'Managing	chronic	obstructive	
pulmonary	disease'	(Aust	Prescr	2007;30:59–63).	There	is	
worldwide	evidence	that	this	genetic	problem	is	much	more	
common	than	it	was	thought	in	the	past.	In	fact	the	World	
Health	organization	advises	that	everybody	with	chronic	
obstructive	pulmonary	disease	should	be	tested	for	alpha-1	
antitrypsin	deficiency,	especially	since	there	is	treatment	for	
it,	though	no	cure.
Michael	A	Kennedy
General	practitioner,	retired
Vaucluse,	nSW
Professor Michael Abramson, Associate Professor Christine 
McDonald and Professor Nicholas Glasgow, authors of the 
article, comment:
We	thank	Dr	Kennedy	for	drawing	attention	to	the	role	
of	alpha-1	antitrypsin	deficiency	in	chronic	obstructive	
pulmonary	disease	(CoPD).	This	genetic	disorder	is	evidence	
for	the	elastase–antielastase	hypothesis	of	emphysema.	The	
prevalence	of	severe	homozygous	(ZZ)	alpha-1	antitrypsin	
deficiency	has	been	estimated	at	around	1/4,727	in	European	
populations.1	Although	75–85%	of	such	individuals	will	
develop	emphysema,	tobacco	smoking	is	still	the	most	
important	risk	factor	for	CoPD	even	in	this	group.	Targeted	
screening	suggests	1–4.5%	of	patients	with	CoPD	have	
underlying	severe	alpha-1	antitrypsin	deficiency.2	The	
index	of	suspicion	should	be	high	in	younger	patients	
with	predominantly	basal	disease	and	a	family	history.	The	
diagnosis	can	be	made	by	measuring	serum	levels	of	alpha-1	
trypsin.	If	they	are	reduced,	genotyping	should	be	performed.	
Whether	people	who	are	heterozygous	(MZ,	MS)	are	also	at	
an	increased	risk	of	CoPD	remains	controversial.
Although	replacement	therapy	is	available,	trials	conducted	
to	date	have	been	underpowered	to	confirm	beneficial	
effects	on	the	rate	of	decline	in	lung	function	or	on	survival.	
one	placebo-controlled	randomised	trial	suggested	some	
reduction	in	the	loss	of	lung	tissue	as	assessed	by	CT	
scan.3	Therapy	involves	intravenous	administration	of	
alpha-1	trypsin	concentrate	purified	by	fractionation	of	
normal	human	plasma	or	recombinant	alpha-1	trypsin.	
These	products	can	restore	alpha-1	trypsin	levels	above	the	
protective	threshold	for	some	weeks.	Replacement	therapy	
is	available	through	the	Special	Access	Scheme.	A	national	
patient	support	group	can	be	contacted	at	http://health.
groups.yahoo.com/group/Alpha1-AnZ.
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A century of concern about complementary medicines
Editor,	–	The	comment	in	Australian Prescriber	(2007;30:91)	
draws	unhelpful	and	misleading	parallels	between	
complementary	medicines	today	and	'dangerous	and	useless	
medicines'	available	100	years	ago.	
The	author	is	right	to	point	to	the	establishment	of	the	
Therapeutic	Goods	Administration	(TGA)	as	an	important	
landmark	for	the	regulation	of	pharmaceuticals	and	
complementary	medicines.	The	Complementary	Healthcare	
Council	(CHC)	fully	supports	a	regulatory	process	that	
safeguards	consumer	interests.	However,	to	suggest	
that	complementary	medicines	as	therapeutic	goods	are	
somehow	compromised	by	false	or	misleading	advertising	or	
that	barriers	exist	to	understanding	them	because	sponsors	
hide	behind	'commercial-in-confidence'	is	inaccurate.
All	advertisements	for	therapeutic	goods	are	subject	to	
the	Therapeutic	Goods,	Trade	Practices	and	other	relevant	
laws.	The	Therapeutic	Goods	Advertising	Code,	which	
applies	to	advertisements	directed	to	consumers	and	where	
sanctions	apply	for	breaches,	requires	material	to	be	truthful,	
balanced,	not	contain	misleading	or	exaggerated	claims,	and	
all	descriptions,	claims	and	comparisons	must	be	able	to	be	
substantiated.	
With	regard	to	'commercial-in-confidence',	it	is	hard	to	see	
how	concerns	regarding	transparency	would	not	equally	
apply	to	pharmaceutical	companies.	Companies	responsible	
for	marketing	products	are	obliged	to	make	available	all	
evidence	regarding	claims	in	relation	to	their	products,	
should	they	be	asked	to	do	so	by	the	TGA.
What	does	concern	the	CHC,	is	the	outdated	attitudes	
demonstrated	towards	complementary	medicines,	despite	
repeated	and	compelling	evidence	demonstrating	their	
health	benefits.	Let's	imagine	for	one	moment	the	implication	
for	pregnant	women	globally,	if	folate	supplementation	in	
preventing	neural	tube	defects	had	not	become	accepted	
mainstream	practice.
Tony	Lewis
Executive	Director
Complementary	Healthcare	Council
Canberra
Dr JS Dowden, the author of the comment, responds:
There	is	Level	1	evidence	to	support	the	use	of	folate	
supplements	by	women	planning	pregnancy.	It	is	doubtful	
that	such	strong	evidence	exists	for	many	complementary	
products.	Given	the	plethora	of	complementary	medicines	
it	is	unlikely	that	the	TGA	has	the	resources	to	assess	the	
evidence	for	many	of	these	products.	Evidence	of	a	product's	
safety	and	efficacy	should	not	be	'commercial-in-confidence'	
irrespective	of	whether	it	is	a	prescription	or	a	non-
prescription	drug.
Despite	the	somewhat	confusing	regulatory	system,	
there	are	plenty	of	complaints	about	the	advertising	of	
complementary	medicines.1	The	usual	sanction	for	an	
unacceptable	advertisement	seems	to	be	a	request	for	
the	advertisement	to	be	withdrawn,	but	it	is	unclear	how	
effectively	this	is	enforced.2
octavius	Beale	was	concerned	about	the	outrageous	claims	
being	made	by	medicines	manufacturers	in	the	early	
20th	century.3		The	number	of	justified	complaints	in	2007	
suggests	that	there	is	still	a	problem.1
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Magnesium
Editor,	–	In	the	article	on	magnesium	by	Dr	Wu	and	Dr	Carter	
(Aust	Prescr	2007;30:102–5)	there	is	little	attempt	to	address	
the	issue	of	cramps	and	magnesium	ingestion	by	the	public.	
My	clinical	experience	has	been	that	every	aged	patient	
who	has	any	problem	with	cramping,	has	either	tried,	or	is	
on,	oral	magnesium	usually	from	the	supermarket	or	health	
store.	This	is	often	magnesium	phosphate.
Could	the	authors	comment	on	the	issue	of	cramping	and	
adults	over	the	age	of	fifty	years?	Is	there	any	evidence	that	
lack	of	magnesium	causes	this,	or	that	oral	magnesium	is	of	
any	benefit?
Chris	Commens
Dermatologist
Pennant	Hills,	nSW
Dr J Wu and Dr A Carter, authors of the article, comment:
In	response	to	Professor	Commens,	a	literature	search	
performed	in	consultation	with	our	pharmacology	unit	
failed	to	raise	any	conclusive	evidence	that	magnesium	
phosphate	is	useful	in	preventing	cramps	in	the	elderly.	This	
is	not	to	say	that	biochemically	proven	hypomagnesaemia	
would	not	respond	to	supplementation,	in	the	same	way	as	
hypocalcaemia	or	hypokalaemia	would	require	calcium	or	
potassium	supplementation	respectively.
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Top 10 drugs
These	tables	show	the	top	10	subsidised	drugs	in	2006–07.			The	tables	do	not	include	private	prescriptions.
Table 1
Top 10 drugs supplied by DDD*/1000 pop/day †
Drug PbS/RPbS ‡
1.	 atorvastatin	 131.799
2.	 simvastatin	 58.072
3.	 ramipril	 30.451
4.	 perindopril	 21.681
5.	 aspirin	 18.01
6.	 omeprazole	 17.996
7.	 frusemide	 17.984
8.	 irbesartan	 17.28
9.	 salbutamol	 17.116
10.	 esomeprazole	 16.802
Table 2
Top 10 drugs by prescription counts †
Drug PbS/RPbS ‡
1.	 atorvastatin	 10	000	495
2.	 simvastatin	 6	231	212
3.	 esomeprazole	 4	428	530
4.	 omeprazole	 3	882	359
5.	 paracetamol	 3	754	140
6.	 perindopril	 3	633	536
7.	 atenolol	 3	217	151
8.	 irbesartan	 2	989	359
9.	 pantoprazole	 2	922	724
10.	metformin	hydrochloride	 2	822	776
Table 3
Top 10 drugs by cost to Government †
Drug Cost to Government  DDD/1000/day  Prescriptions 
  ($A)  PbS/RPbS ‡ PbS/RPbS ‡  
1.	 atorvastatin	 562	234	406	 131.799	 10	000	495
2.	 simvastatin	 309	227	367	 58.072	 6	231	212
3.	 clopidogrel	 179	983	732	 9.219	 2	404	361
4.	 esomeprazole	 161	102	420	 16.802	 4	428	530
5.	 olanzapine	 157	471	533	 3.073	 775	475
6.	 salmeterol	and	fluticasone	 157	239	113	 –	§	 2	789	814
7.	 omeprazole	 114	030	881	 17.996	 3	882	359
8.	 pravastatin	 		93	389	809	 13.537	 1	870	879
9.	 venlafaxine	 		93	329	210	 11.987	 2	318	531
10.	 tiotropium	bromide	 		91	223	529	 5.289	 1	303	682
*	 The	defined	daily	dose	(DDD)/thousand	population/day	is	a	more	useful	measure	of	drug	utilisation	than	prescription	counts.	It	
shows	how	many	people,	in	every	thousand	Australians,	are	taking	the	standard	dose	of	a	drug	every	day.
†	 Based	on	date	of	supply
‡	 PBS	Pharmaceutical	Benefits	Scheme,	RPBS	Repatriation	Pharmaceutical	Benefits	Scheme
§	 Combination	drugs	do	not	have	a	DDD	allocated
Source:	Drug	Utilisation	Sub-Committee	(DUSC)	Drug	Utilisation	Database,	as	at	11	october	2007.	©	Commonwealth	of	Australia.
NPS RADAR December 2007
Strontium	ranelate:		The	PBS	listing	for	the	osteoporosis	drug	
strontium	ranelate	has	been	extended	to	allow	treatment	of	
postmenopausal	women	without	an	existing	fracture	and	a	
bone	mineral	density	T-score	≤	–3.0	(primary	prevention).	The	
latest	issue	of	NPS RADAR describes	the	place	in	therapy	of	
strontium	relative	to	other	anti-resorptive	agents.
It	also	contains	information	on:	
n	 the	listing	of	the	anticonvulsant	drug	topiramate	as	an	
alternative	treatment	for	migraine	prevention,	for	adults	
unable	to	tolerate	beta	blockers	or	pizotifen	
n	 updated	safety	information	for	the	glitazones	–	rosiglitazone	
and	pioglitazone.	
See	the	complete	reviews	at	www.npsradar.org.au
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Drugs for the doctor's bag
Andrew Baird, General Practitioner, Brighton, Victoria
Summary 
The doctor's bag should contain drugs for medical 
emergencies that may occur in the community. 
Most of these drugs are provided under the 
Pharmaceutical benefits Scheme and can be 
ordered free of charge through a pharmacist. 
General practice accreditation now requires that 
clinics have appropriate emergency drugs as well 
as oxygen and a bag-valve-mask system. Practices 
should also have an up-to-date logbook detailing 
the emergency drug stocks and a system for 
checking that the drugs have not expired. 
Key	words:	medical	emergencies,	Pharmaceutical	Benefits	
Scheme.
(Aust Prescr 2007;30:143–6)
introduction
Traditionally	the	doctor's	bag	contains	drugs	and	equipment	
for	managing	medical	emergencies	that	present	in	the	clinic	or	
in	the	community.1,2,3		The	frequency	and	type	of	emergencies	
that	occur	depend	on	the	location	and	nature	of	the	practice.	
With	the	increasing	availability	of	skilled	Mobile	Intensive	Care	
Ambulance	(MICA)	paramedics	as	'first	responders',	many	
general	practitioners	have	become	less	involved	in	managing	
emergencies.	However,	in	rural	and	remote	areas	the	doctor	will	
often	be	the	'first	responder'	and	may	be	working	with	volunteer	
ambulance	crews.
what to carry
Doctors	should	consider	the	medical	emergencies	that	they	
may	encounter	in	their	practice	and	select	appropriate	drugs	for	
their	doctor's	bag	(Table	1).	Many	of	these	drugs	are	provided	
under	the	Pharmaceutical	Benefits	Scheme	(PBS)	as	Emergency	
drug	(Doctor's	bag)	supplies.4	Most	of	them	are	injectable.	
However,	there	are	some	non-injectable	drugs	which	are	useful	
in	emergencies,	such	as	soluble	aspirin,	glyceryl	trinitrate	
(sublingual	spray)	and	salbutamol	aerosol.	
Doctors	can	submit	a	monthly	order	form*	to	a	pharmacist	for	
the	supply	of	PBS	doctor's	bag	emergency	drugs	at	no	cost.	
Some	PBS	drugs	are	supplied	as	paired	alternatives.	These	
include	hydrocortisone	or	dexamethasone	and	metoclopramide	
or	prochlorperazine.	A	group	practice	can	have	all	of	these	drugs	
available	if	doctors	agree	to	order	one	or	other	item	in	each	pair.	
A	drug	can	only	be	requested	if	the	doctor	holds	less	than	the	
maximum	quantity	provided	under	the	PBS,	or	to	replace		
date-expired	drugs.
Some	drugs	which	are	useful	for	emergencies	are	not	provided	
under	the	PBS	(Table	1).	Doctors	may	obtain	these	as	private	
items	by	submitting	a	written	order	to	a	pharmacist.	These	
drugs	include:
n	 oral	drugs	such	as	aspirin,	analgesics,	diazepam,	antibiotics,	
prednisolone
n	 non-steroidal	anti-inflammatory	drugs	(nSAIDs)	for	rectal	or	
intramuscular	use
n	 glucose	50%
n	 ceftriaxone
n	 midazolam
n	 ergometrine.
It	is	also	useful	to	carry	at	least	one	1	L	bag	of	normal	saline,	
and	a	supply	of	normal	saline	and	water	for	injections.
Current practice guidelines
Emergency	drugs	available	through	the	PBS	sometimes	differ	
from	those	recommended	by	Australian	treatment	guidelines.	
For	example,	the	use	of	parenteral	chlorpromazine	is	not	
recommended	by	the	Therapeutic	Guidelines	because	it	can	
cause	serious	hypotension.	Instead,	oral	preparations	of	
risperidone,	olanzapine	or	haloperidol	are	recommended	for	
behavioural	emergencies	if	oral	diazepam	is	not	effective.5	
only	injectable	forms	of	diazepam	and	haloperidol	are	
provided	as	emergency	drugs	by	the	PBS.	
Lignocaine	is	a	PBS	doctor's	bag	item.	However,	other	
treatments	for	sustained	ventricular	tachycardia	may	be	
preferred.5
Precautions with emergency drugs
With	sedating	drugs,	there	is	a	risk	of	death	from	respiratory	
depression,	especially	when	given	intravenously.	It	is	
therefore	important	to	keep	the	patient	under	observation	after	
administration	of	these	drugs.	
Pethidine	is	no	longer	supplied	as	a	doctor's	bag	item.6	Instead,	
an	injectable	form	of	tramadol	is	now	available	through	the	PBS.	
Tramadol	should	not	be	used	in	patients	taking	a	serotonergic	
antidepressant	because	of	the	risk	of	serotonin	syndrome.	
Doctors	should	be	aware	that	ketorolac	should	not	be	given	to	
patients	with	renal	impairment.	*	 order	forms	are	obtainable	from	Medicare	Australia,		
phone	13	22	90.
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Table 1
useful drugs for the doctor's bag
Drug (form) indications Contraindications Cautions
Adrenaline		
(1	mg	in	1	mL	injection)
Cardiac	arrest,	anaphylaxis7	 none	in	cardiac	arrest	or	
anaphylaxis
May	cause	arrhythmia	
and	myocardial	or	
cerebrovascular	ischaemia
†	Aspirin,	soluble,		
300	mg	tablet
Acute	coronary	syndrome,	
migraine
Peptic	ulcer,	bleeding	disorders none
Atropine	sulfate		
(600	microgram	in		
1	mL	injection)
Bradycardia,	asystole	 none	in	cardiac	arrest	or	
hypotensive	bradycardia
May	cause	tachycardia,	
confusion	and	nausea
Benztropine	mesylate		
(2	mg	in	2	mL	injection)
Acute	dystonic	reactions Children	<	3	years	 May	cause	tachycardia	and	
confusion
Benzylpenicillin		
(600	mg	or		
3	g	of	powder)
Severe	infections	
(meningococcaemia,	
pneumonia,	septicaemia)
Allergy none
†	Ceftriaxone		
(2	g	powder)
Severe	infections	
(meningococcaemia,		
pneumonia,	septicaemia)
Allergy none
Dexamethasone	sodium	
phosphate		
(4	mg	in	1	mL	injection)
Acute	allergic	reactions	
(anaphylaxis,	severe	
asthma),	severe	croup,	acute	
Addisonian	crisis.	Palliative	care	
emergencies8
none	in	emergency none
Diazepam		
(10	mg	in	2	mL	injection)
Acute	anxiety,	convulsions	(can	
be	given	rectally)
Cardiorespiratory	failure,
CnS	depression	
May	cause	drowsiness,	
confusion	and	respiratory	
depression
Dihydroergotamine	
mesylate		
(1	mg	in	1	mL	injection)
Migraine Hemiplegic	migraine,	use	of	
sumatriptan
Vasospasm	syndromes	can	
occur	but	are	rare
Diphtheria	and	tetanus	
vaccine		
(0.5	mL	injection)
Tetanus	and	diphtheria	
prophylaxis	following	injury
Children	<	8	years	 May	cause	pain	and	swelling	
locally	and	fever	and	malaise
†	Ergometrine	maleate		
(500	microgram	in	1	mL)
Postpartum	haemorrhage	and	
incomplete	abortion	
Threatened	abortion,	severe	
hypertension	
May	cause	hypertension,	
headache	and	nausea
Frusemide		
(20	mg	in	2	mL	injection)
Acute	pulmonary	oedema Sulfonamide	allergy none
Glucagon	hydrochloride		
(1	mg	in	1	mL	injection)
Hypoglycaemia	 none none
†	Glucose	50%		
(500	mg/mL	in	50	mL)
Hypoglycaemia	 Diabetic	coma	 May	cause	phlebitis
Glyceryl	trinitrate		
(400	microgram	dose		
per	spray)
Acute	coronary	syndrome,	
angina,	acute	pulmonary	
oedema	
Cardiogenic	shock	
(SBP	<	90	mmHg)	
May	cause	headache	and	
hypotension
Haloperidol		
(5	mg	in	1	mL	injection)
Acute	psychosis,	acute	mania,	
nausea	and	vomiting
Cardiovascular	collapse	and	
CnS	depression	
May	cause	extrapyramidal	
symptoms,	confusion	and	
hypotension
Hydrocortisone	sodium	
succinate		
(100	mg	or	250	mg	in		
2	mL	injection)
Anaphylaxis,	severe	asthma none	in	emergency none
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†	Ketorolac	
(10	mg	in	1	mL	injection)
Pain Renal	impairment,	
anticoagulation,	asthma,	
treatment	with	probenecid	
May	cause	nausea
Metoclopramide	
hydrochloride		
(10	mg	in	2	mL	injection)	
nausea	and	vomiting,	migraine Acute	complete	bowel	
obstruction
Extrapyramidal	symptoms	
with	increased	risk	of	
dystonic	reactions	in	children
†	Midazolam	
(5	mg	in	1	mL	or		
15	mg	in	3	mL	injection)
Convulsions,	severe	agitation Cardiorespiratory	failure	and	
CnS	depression	
May	cause	drowsiness,	
confusion	and	respiratory	
depression
Morphine	sulphate		
(15	mg	or	30	mg	in		
1	mL	injection)
Severe	pain,	acute	coronary	
syndrome,	acute	pulmonary	
oedema
Respiratory	or	CnS	
depression.	Avoid	using	in	
infants.
May	cause	sedation,	nausea	
and	vomiting
naloxone	hydrochloride		
(2	mg	in	5	mL)
opioid-induced	respiratory	
depression
none People	with	opioid	
dependence	may	experience	
acute	withdrawal	syndrome
Procaine	penicillin
(1.5	g	for	injection)
Severe	infections	
(meningococcaemia,	
pneumonia,	septicaemia)
Allergy none
Prochlorperazine	
(12.5	mg	in	1	mL)
nausea	and	vomiting,	vertigo Circulatory	collapse	and	CnS	
depression	
May	cause	drowsiness	and	
extrapyramidal	symptoms
Promethazine	
hydrochloride	
(50	mg	in	2	mL	
injection)
nausea	and	vomiting,	allergic	
reactions
Children	<	2	years	(except	on	
advice)	
May	cause	drowsiness
Salbutamol	sulfate	
(inhaler	100	microgram/
dose	or	nebuliser	
solution	2.5	mg	or		
5	mg	in	2.5	mL)
Asthma,	bronchospasm none May	cause	tachycardia	or	
tremor
Tramadol	hydrochloride		
(100	mg	in	2	mL	
injection)
Pain Children,	treatment	with	
serotonergic	antidepressants	
or	MAoIs,	respiratory	or	CnS	
depression	
May	cause	nausea,	vomiting	
and	dizziness
Verapamil	hydrochloride	
(5	mg	in	2	mL	injection)
Supraventricular	tachycardia Cardiogenic	shock,	heart	block,	
hypotension,	use	of	beta	
blockers	and	some	SSRIs	
May	cause	nausea,	heart	
block,	bradycardia	and	
hypotension
†	 not	supplied	under	PBS	doctor's	bag	emergency	drugs
CnS	 central	nervous	system
SBP	 systolic	blood	pressure
MAoI	 monoamine	oxidase	inhibitor
SSRI	 selective	serotonin	reuptake	inhibitor
oxygen
oxygen	cylinders	can	be	rented	and	refilled	from	a	medical	gas	
supplier	(for	example	BoC	(British	oxygen	Corporation)).	A	490	L	
(size	C)	will	last	for	55	minutes	at	8	L/min.	Use	high-flow	oxygen	
with	caution	in	patients	at	high	risk	of	carbon	dioxide	retention.
Storage of drugs
Drugs	must	be	stored	in	a	locked	bag	or	a	locked	cupboard	at	
below	25°	C.	Doctor's	bags	should	not	be	left	in	cars	where	
the	temperature	will	easily	exceed	25°	C	on	even	a	mild	day.	
Diphtheria	and	tetanus	vaccine	is	stored	in	a	refrigerator.	
A	register	is	required	to	log	drugs	received	and	drugs	used	
(including	the	recipient's	name).	Schedule	8	drugs	(opioids)	
must	be	stored	in	a	locked,	fixed,	steel	safe,	although	ampoules	
may	be	put	in	a	locked	bag	for	use	away	from	the	clinic.	A	
separate	book	(available	from	the	Royal	Australian	College	of	
General	Practitioners)	is	required	to	log	Schedule	8	drugs	that	
are	received	and	used.
Drug (form) indications Contraindications Cautions
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General practice accreditation
To	meet	accreditation	standards,	general	practices	must	have	
oxygen,	a	bag-valve-mask	system,	and	appropriate	emergency	
drugs.	All	general	practitioners	must	have	access	to	a	doctor's	
bag	(which	may	be	shared	between	two	or	more	general	
practitioners).	There	should	be	a	system	for	checking	emergency	
drug	stocks	and	expiry	dates	–	for	example,	a	monthly	inventory	
by	a	practice	nurse.	Doctor's	bags	should	have	a	sharps	
container,	disposable	gloves,	and	dressing	packs.	Safety	
intravenous	cannulas	and	needleless	systems	reduce	the	risk		
of	needlestick	injury.3
Conclusion
Appropriate	drugs	in	the	doctor's	bag	are	an	essential	part	of	
general	practice.	The	contents	of	the	bag	will	be	tailored	to	suit	
the	needs	of	each	practice.	
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Dental notes
Prepared by Dr M McCullough of the Australian 
Dental Association
Drugs for the doctor's bag
Dentists	do	not	need	to	stock	as	many	emergency	drugs	as	
general	practitioners,	however	we	are	required	to	have	fully	
equipped	and	well	maintained	emergency	equipment	in	our	
surgery.
As	stated	in	the	recently	published		Therapeutic	Guidelines:	
oral	and	Dental1,	the	minimum	requirements	for	emergency	
situations	in	the	dental	surgery	are	oxygen,	a	disposable	airway,	
and	adrenaline.	For	dental	practices	performing	more	extensive	
procedures,	or	with	an	increased	proportion	of	medically	
compromised	patients,	then	more	equipment	and	medications	
are	required.
Medical	emergencies	in	dental	surgeries	are	uncommon	so	
there	is	a	risk	that	medications	will	expire	before	they	are	
needed.	It	is	incumbent	on	dentists	to	ensure	that	the	drugs	in	
their	emergency	equipment	are	not	out	of	date.	Ideally,	there	
should	be	a	system	for	checking	emergency	drug	stocks	and	
expiry	dates,	perhaps	by	a	monthly	inventory.	Many	dental	
practices	probably	already	have	such	an	inventory	and	it	can	be	
easily	foreseen	that	such	documentation	may	well	become	part	
of	any	potential	practice	audit.
Emergency	drugs	are	not	available	under	the	Pharmaceutical	
Benefits	Scheme	for	dentists	and	must	be	purchased	at	full	cost.	
This	anomaly	should	be	redressed.	
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Evaluation of adrenocortical function in adults
Jui Ho, Endocrinologist, and David J Torpy, Associate Professor, Discipline of Medicine,  
University of Adelaide, and Endocrine and Metabolic Unit, Royal Adelaide Hospital, and  
Hanson Institute, Adelaide
Abnormal	laboratory	results
Summary
Cushing's syndrome is caused by increased 
concentrations of cortisol. Most cases can be 
detected by measuring the free cortisol in a urine 
sample collected over 24 hours. in Cushing's 
syndrome the increased secretion of cortisol is 
not reduced during a dexamethasone suppression 
test. Addison's disease is caused by a decreased 
secretion of cortisol that does not respond to 
an injection of synthetic adrenocorticotrophic 
hormone. Concentrations of adrenocorticotrophic 
hormone are raised in primary, and low or normal 
in secondary adrenal insufficiency. Some patients 
with hypertension have primary aldosteronism. 
They have a high ratio of aldosterone to plasma 
renin activity. when investigating adrenal function 
it is important to consider the patient's diet and 
drugs as well as the timing of the sample.
Key	words:	Addison's	disease,	aldosterone,	Conn's	syndrome,	
cortisol,	Cushing's	syndrome.
(Aust Prescr 2007;30:147–9)
introduction
The	adrenal	cortex	consists	of	three	functionally	separate	
layers.	The	outer	zona	glomerulosa	produces	aldosterone	
under	the	stimulatory	control	of	the	renin-angiotensin	system	
and	potassium.	Aldosterone	increases	sodium	reabsorption	
and	potassium	excretion	in	the	kidney	and	gut.	The	zona	
fasciculata	produces	cortisol	under	the	control	of	pituitary	
adrenocorticotrophic	hormone	(ACTH).	ACTH	is	principally	
regulated	by	hypothalamic	corticotrophin-releasing	hormone.	
The	secretion	of	ACTH	responds	to	a	diurnal	rhythm,	stress	and	
negative	feedback	from	circulating	cortisol.	Cortisol	regulates	
metabolism,	and	during	stress	it	restrains	and	redirects	the	
immune	system	and	accentuates	cardiovascular	responses.	
The	inner	zona	reticularis	produces	the	adrenal	androgens	
dehydroepiandrosterone	and	androstenedione.	
Clinical	evaluation	determines	which	tests	of	adrenal	function	
are	needed.	The	principles	of	testing	include:
n	 using	basal	hormone	concentrations	for	screening
n	 using	suppression	or	stimulation	tests	to	definitively	
diagnose	hormone	excess	or	deficiency
n	 measuring	trophic	hormones	to	diagnose	the	site	
of	endocrine	lesions	(for	example,	measuring	ACTH	
to	distinguish	an	adrenal	from	a	pituitary	lesion	in	
hypocortisolism).
Testing for hypercortisolism (Cushing's 
syndrome)
Mild	Cushing's	syndrome	is	notoriously	difficult	to	diagnose,	
but	early	diagnosis	avoids	disability	and	reduces	mortality.	
Cortisol	concentrations	increase	in	Cushing's	syndrome,	but	
there	are	two	major	confounders.	one	is	that	some	patients	
have	increased	cortisol	production	rates	that	remain	within	the	
statistically	normal	range.	Furthermore,	this	overproduction	
may	be	intermittent	or	cyclic.	Secondly,	some	individuals	may	
have	transient	hypercortisolism	and	features	consistent	with	
early	Cushing's	syndrome,	but	without	the	progressive	catabolic	
effects.	These	individuals	have	'pseudo-Cushing's'.	In	some	
cases	this	is	associated	with	alcohol	abuse	or	depression.	no	
single	test	is	infallible	in	Cushing's	syndrome	and	values	close	
to	the	limits	of	normal	must	be	regarded	with	suspicion.1
Screening tests for Cushing's syndrome
Most	cases	can	be	readily	diagnosed	by	an	elevation	of	the	free	
cortisol	in	a	24-hour	collection	of	urine,	however	in	up	to	15%	
of	new	cases	the	result	may	be	normal.	The	dexamethasone	
suppression	test	also	has	a	substantial	false	positive	and	false	
negative	rate.	The	diagnosis	can	be	made	with	plasma	cortisol,	
but	the	blood	sample	has	to	be	taken	at	midnight	and	this	
is	often	impractical.	A	midnight	value	less	than	120	nmol/L	
virtually	excludes	Cushing's	syndrome.
Urinary free cortisol
over	24	hours	the	free	cortisol	provides	an	integrated	
assessment	of	cortisol	secretion.	This	avoids	the	pitfalls	of	
blood	tests	including	circadian	rhythm,	pulsatile	cortisol	release	
and	altered	levels	of	corticosteroid-binding	globulin.	However,	
148 |   VoLuME 30   |   NuMbER 6   |  DECEMbER 2007 
urine	volumes	above	four	litres	per	day	may	result	in	false	
positive	tests.
Cortisol	excretion	rates	vary	diurnally	but	urine	creatinine	
excretion	does	not.	Hence,	it	is	not	possible	to	correct	an	
incomplete	or	over-collection	with	the	24-hour	urine	creatinine.	
Urinary	creatinine	is	useful	in	determining	if	the	urine	collection	
was	adequate,	for	example	a	low	24-hour	urine	creatinine	in	
a	large	person	may	suggest	under-collection.	In	addition,	in	
sequential	measurements	the	24-hour	urine	creatinine	should	
not	vary	by	more	than	10%.
False	positive	results	can	occur	in	patients	with	high	urine	
volumes,	chronic	alcoholism,	depression,	idiopathic	pseudo-
Cushing's,	or	serious	illness.	False	negatives	may	occur	in	
patients	with	early	or	mild	Cushing's	syndrome,	or	in	those	with	
cyclic	hypercortisolism	which	occurs	in	10%	or	more	of	cases	
depending	on	how	cyclic	is	defined.
Midnight plasma cortisol
Cortisol	peaks	around	the	time	of	waking,	decreases	rapidly	
through	the	morning	and	reaches	a	nadir	around	midnight.	Most	
patients	with	Cushing's	syndrome	have	early	morning	plasma	
cortisol	concentrations	within	or	slightly	above	the	normal	range.	
In	contrast,	midnight	plasma	cortisol	concentrations	are	almost	
always	high	(greater	than	207	nmol/L).	
Midnight salivary cortisol
Salivary	cortisol	concentrations	reflect	plasma	free	cortisol,	but	
appropriate	assay-specific	normative	values	must	be	used	for	
its	interpretation.	Internationally,	cut-offs	have	ranged	widely.	
We	have	found	a	cut-off	of	13	nmol/L	to	reliably	distinguish	
Cushing's	from	non-Cushing's	patients.
Low-dose dexamethasone suppression testing
A	low	dose	of	dexamethasone	should	suppress	plasma	cortisol.	
This	is	commonly	used	as	a	screening	test	for	Cushing's	
syndrome.	Dexamethasone,	1	mg	orally,	is	given	at	11	pm	and	
plasma	cortisol	is	measured	at	8–9	am	the	next	day	to	see	if	it	
has	been	suppressed.	The	dexamethasone	suppression	test	has	
been	variously	validated	in	the	past,	often	with	inappropriate	
controls,	such	as	normal	volunteers.	Low	cut-off	values		
(50	nmol/L	or	less)	tend	to	over-diagnose,	while	high	cut-off	
values	(140	nmol/L	or	above)	tend	to	miss	cases	of	Cushing's	
syndrome.	False	positive	results	can	occur	in	acute	illness,	
depression,	anxiety,	alcoholism,	high	oestrogen	states	and	
with	drugs	that	accelerate	dexamethasone	metabolism.	If	a	low	
dose	does	not	suppress	cortisol,	a	high-dose	dexamethasone	
suppression	test	is	indicated.
Testing for primary hypoadrenalism (Addison's 
disease) and ACTH deficiency
Hypoadrenalism	may	be	caused	by	abnormalities	in	the	adrenal	
gland	or	a	lack	of	ACTH.	Adrenal	suppression	is	also	an	adverse	
effect	of	corticosteroids.
Although	fatigue	is	a	key	symptom	of	hypoadrenalism,	most	
fatigued	people	have	normal	adrenal	function.	There	is	no	single	
cheap	and	convenient	test	for	evaluating	hypoadrenalism.2	Testing	
includes	an	ACTH	stimulation	test,	and	measurements	of	sodium,	
potassium,	ACTH,	plasma	cortisol,	aldosterone	and	renin	activity.
Plasma cortisol
An	early	morning	plasma	cortisol,	measured	within	one	
hour	of	waking,	below	200	nmol/L	strongly	suggests	adrenal	
insufficiency.	Conversely,	a	plasma	cortisol	greater	than		
500	nmol/L	excludes	the	diagnosis	and	obviates	the	need	for	an	
ACTH	stimulation	test.	Intermediate	cortisol	concentrations	may	
require	investigation	with	an	ACTH	stimulation	test.	
ACTH stimulation testing
In	most	cases	of	suspected	hypoadrenalism,	a	stimulation	test	
is	needed	to	diagnose	cortisol	deficiency.	A	normal	response	to	
intravenous	ACTH	(250	microgram)	is	a	cortisol	peak	value	at	
either	30	or	60	minutes	of	greater	than	500	nmol/L.	The	previously	
recommended	additional	criterion	of	a	cortisol	increment	greater	
than	200	nmol/L	rarely	contributes	to	the	diagnosis.
There	are	cases	of	missed	adrenal	insufficiency	after	a	normal	
ACTH	test.	The	reproducibility	of	testing	is	imperfect.	The	test	
has	not	been	validated	against	clinical	end	points,	but	has	been	
validated	against	the	now	rarely	used	insulin	hypoglycaemia	test.
Plasma ACTH
Measurement	of	plasma	ACTH	helps	localise	the	cause	of	
adrenal	insufficiency	–	adrenal	(primary	or	Addison's)	versus	
pituitary	(secondary)	or	hypothalamic	(tertiary).	In	primary	
adrenal	insufficiency,	plasma	ACTH	is	greatly	elevated	due	to	a	
lack	of	the	negative	feedback	of	cortisol	on	the	hypothalamic-
pituitary	axis.	In	secondary	or	tertiary	adrenal	insufficiency,	
ACTH	is	low	or	inappropriately	normal.
Corticotrophin-releasing hormone test
The	use	of	corticotrophin-releasing	hormone	to	test	ACTH	and	
cortisol	reserve	directly	assesses	pituitary	and	adrenal	function.	
other	than	minor	flushing,	corticotrophin-releasing	hormone		
(1	microgram/kg	intravenously)	rarely	produces	adverse	effects.	
The	test	is	expensive	and	corticotrophin-releasing	hormone	is	
not	widely	available.
Testing for primary aldosteronism
Conn's	syndrome	is	hypertension	and	hypokalaemia	due	to	an	
aldosterone-secreting	adrenal	tumour,	however	many	cases	are	
normokalaemic.	Screening	for	primary	aldosteronism	may	be	
indicated	in	patients	with	hypertension	who	have	spontaneous	
or	thiazide-induced	hypokalaemia.3	
Plasma aldosterone concentration:plasma 
renin activity ratio
A	mid-morning	blood	sample	is	taken	from	a	seated	patient.	
In	primary	aldosteronism,	the	plasma	renin	activity	is	reduced	
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and	the	plasma	aldosterone	concentrations	are	high,	resulting	
in	a	plasma	aldosterone	concentration	(pmol/L):plasma	renin	
activity	(ng/mL/hr)	ratio	of	greater	than	700.	A	false	positive	
may	occur	with	low	aldosterone	concentrations	if	the	plasma	
renin	activity	is	very	low,	for	example	in	patients	taking	a	high	
salt	diet.	Hence,	an	elevated	ratio	may	not	suggest	primary	
aldosteronism	if	the	plasma	aldosterone	concentration	is	less	
than	270	nmol/L.
Serum	potassium	should	be	measured	simultaneously	as	
a	low	serum	potassium	will	reduce	the	plasma	aldosterone	
concentration	and	indicate	a	requirement	to	replace	potassium	
before	testing	again.	Antihypertensive	drugs,	except	for	
hydralazine,	prazosin	and	verapamil,	can	also	interfere	with	
the	plasma	aldosterone	concentration:plasma	renin	activity	
ratio.	Diuretics	and	aldosterone	receptor	blockers	such	as	
spironolactone	need	to	be	stopped	for	six	weeks	before	testing.	
Beta	blockers	suppress	the	plasma	renin	activity	but	they	
can	be	stopped	for	24–48	hours	before	testing.	The	effects	of	
angiotensin	converting	enzyme	(ACE)	inhibitors	and	angiotensin	
receptor	antagonists	are	generally	minor,	but	in	a	patient	treated	
with	these	drugs	a	detectable	plasma	renin	activity	level	or	a	
low	plasma	aldosterone	concentration:plasma	renin	activity	
ratio	does	not	exclude	the	diagnosis	of	primary	aldosteronism.	
Dihydropyridine	calcium	antagonists	such	as	nifedipine	and	
amlodipine	can	reduce	the	plasma	aldosterone	concentration	
in	patients	with	an	aldosterone	secreting	adenoma.	Renal	
impairment	may	elevate	the	ratio	as	increased	potassium	
elevates	aldosterone	secretion	while	salt	and	water	retention	
suppresses	the	plasma	renin	activity.
Confirming primary hyperaldosteronism
Confirmatory	testing	aims	to	demonstrate	aldosterone	
secretory	autonomy,	using	measurements	of	plasma	or	urine	
aldosterone	under	salt	loading	conditions,	with	or	without	
fludrocortisone.	The	final	step	is	to	determine	if	one	or	both	
adrenals	are	the	source	of	aldosterone,	generally	requiring	
adrenal	vein	sampling.
Adrenal incidentaloma
An	unanticipated	adrenal	mass	(incidentaloma)	is	found	in	
approximately	4%	of	upper	abdominal	computed	CT	scans.	
Clinical,	imaging	and	biochemical	evaluation	is	necessary	to	
exclude	malignancy	and	hormone	excess.4	The	risk	of	
adrenocortical	cancer	is	very	low,	but	adrenal	metastases	are	
common	and	need	to	be	considered	in	patients	with	a	history		
of	cancer.	
Conclusion
Disorders	of	adrenocortical	function	are	uncommon	and	the	
symptoms	often	non-specific.	Application	of	a	small	number	of	
biochemical	screening	tests	can	separate	those	patients	who	do	
not	have	a	disorder	of	adrenal	function	from	those	who	require	
specialised	assessment	and	more	complex	testing.
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Self-test questions
The following statements are either true or false  
(answers on page 167)
1.	 Most	patients	with	primary	hyperaldosteronism	have	
hyperkalaemia.
2.	 A	normal	24-hour	urine	free	cortisol	excludes	Cushing's	
syndrome.
Therapeutic Advice and information Service (TAiS)
A telephone service for health professionals 
Telephone 1300 138 677 (local call charge)
The	national	Prescribing	Service	Therapeutic	Advice	and	
Information	Service	(TAIS)	is	a	national	telephone	service	
for	general	practitioners,	community	pharmacists	and	other	
health	professionals.	For	the	cost	of	a	local	call,	TAIS		
provides	independent	drug	and	therapeutics	information	
on	topics	such	as	new	drugs,	use	of	drugs	for	unlicensed	
indications,	interactions	between	drugs,	foods	or	
complemetary	therapies,	adverse	effects,	and	the	safety	of	
drugs	in	pregnancy	and	lactation.	
Contact:  office	hours Monday	to	Friday,	except	national		
	 public	holidays
Telephone:		 1300	138	677	(local	call	charge)	
Fax:		 (03)	9459	4546	
Email:		 tais@nps.org.au	
Mail:		 Austin	Health	Drug	Information	
	 Pharmacy	Department	
	 Austin	Hospital	
	 145	Studley	Road	
	 HEIDELBERG	VIC	3084
For	non-urgent	enquiries	you	can	also	use	the	TAIS	online	
enquiry	form	on	the	nPS	website.	
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Relationships between health professionals and 
industry: maintaining a delicate balance
Paul A Komesaroff, Professor of Medicine, Director, Centre for the Study of Ethics in 
Medicine and Society, Monash University Department of Medicine, Alfred Hospital, 
Melbourne, and Ethics Convener, Royal Australasian College of Physicians
Summary
The power and influence of the pharmaceutical 
industry has raised concerns among health 
professionals and the wider community and led 
to calls for increased regulation. overwhelming 
evidence that advertising, contact with company 
representatives, gift giving, sponsorship of 
meetings and other forms of promotion influence 
prescribing behaviour, has drawn particular 
attention to drug promotion. in answer to these 
concerns a range of responses has developed, 
including rules set by government, processes for 
the review and management of research, industry 
codes of conduct, community responses, and 
guidelines generated by practitioner associations. 
The various forms of regulation taken together 
strike a delicate balance that aims to protect 
the interests of the community and individual 
patients, foster research and the development 
of new products, maintain public confidence 
in pharmaceuticals and medicine, and facilitate 
ethical decision making among the various 
participants. Although guidelines for health 
professionals provide some advice, they cannot 
cover all situations where conflicts and dualities 
may arise in practice.
Key	words:	drug	promotion,	drug	regulation,	ethics.
(Aust Prescr 2007;30:150–3)
introduction
Despite	improvements	achieved	in	the	management	of	complex	
medical	conditions	in	recent	years	and	widespread	and	
increasing	use	of	pharmaceuticals,	the	pharmaceutical	industry	
has	been	increasingly	portrayed	in	both	the	academic	literature	
and	the	popular	media	in	an	unfavourable	light.	While	it	may	
be	true	that	the	industry's	negative	reputation	is	not	completely	
justified,	it	is	not	difficult	to	understand	the	source	of	the	
concerns.
General	practitioners	and	other	health	professionals	such	
as	pharmacists	are	frequently	visited	by	representatives	of	
pharmaceutical	companies.	The	purpose	of	these	visits	is	to	
promote	the	company's	drugs	and	to	build	a	relationship.	In	
dealing	with	such	encounters,	situations	may	arise	where	there	
is	an	ethical	dilemma	or	conflict	of	interest.	It	is	important	
for	health	professionals	to	be	aware	of	these	and	to	respond	
appropriately.
Drug promotion
In	Australia	the	primary	targets	of	drug	promotion	are	doctors,	
who	may	be	provided	with	gifts,	offers	of	travel,	and	other	
inducements	to	prescribe.1	More	subtle	promotion	may	include	
educational	activities,	drug	samples	and	drug	familiarisation	
schemes,	and	support	for	the	practice	such	as	providing	a	nurse	
to	collect	data.	
Even	though	doctors	generally	deny	that	they	are	influenced	
by	such	approaches2,3,	there	is	overwhelming	evidence	that	
advertising	influences	prescribing	behaviour.	Physicians	
who	attend	pharmaceutical	events	are	more	likely	to	use	the	
products	of	the	sponsors,	even	in	the	absence	of	reliable	and	
credible	evidence	in	their	favour.4,5	Promotional	activities	in	
general	lead	to	increased	prescribing	of	drugs,	acceptance	of	
commercial	rather	than	scientific	views,	a	propensity	to	engage	
in	non-rational	prescribing	behaviour6,7,8,	and	biases	in	favour	of	
a	company's	drugs.9,10	
While	research	undertaken	by	industry	is	often	rigorous	and	
well	conducted,	it	may	be	driven	by	commercial	imperatives	
leading	to	biased	presentation	and	interpretation	of	results.11,12	
Protocols	and	methodologies	may	reflect	and	support	intended	
outcomes	rather	than	disinterested	inquiry.13	
Perhaps	of	even	greater	concern	is	the	well	documented	fact	
that	industry	interests	substantially	influence	the	social	agenda	
relating	to	the	understanding	of	health	and	disease,	sexuality,	
body	image	and	lifestyles.14,15
What is special about drug promotion?
Concern	about	the	role	and	influence	of	the	pharmaceutical	
industry	is	heightened	because	of	the	special	features	of	
medicines	compared	to	other	commercial	products.	The	
consumers	of	medications	are	often	extremely	vulnerable,	for	
the	obvious	reason	that	their	health	may	be	at	stake	in	using	a	
product.	Decisions	about	what	drugs	to	use	are	often	taken	
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not	by	them	alone	but	by	their	medical	practitioners,	whose	
interests	are	not	always	identical	to	those	of	their	patients.	
For	prescription	drugs,	medical	practitioners	have	great	
influence	and	are	charged	with	the	responsibility	of	balancing	
patients'	needs	and	the	public	interest.	They	have	knowledge	
and	expertise	to	assess	the	scientific	evidence,	and	access	to	the	
specific	contextual	details	of	medical	need	in	particular	cases.	
For	over-the-counter	products,	pharmacists	advise	patients	and	
directly	benefit	from	making	a	sale.	They	may	also	be	offered	
incentives	to	stock	particular	brands.
The	ongoing	debates	about	the	role	and	power	of	the	drug	
industry	in	the	popular	media16,17,18	have	no	doubt	influenced	
community	attitudes,	although	it	is	difficult	to	determine	just	
what	impact	these	may	have	had.	While	some	consumer	
groups	have	expressed	suspicion	and	hostility	to	the	industry,	
other	groups	have	emphasised	the	importance	of	improved	
co-operation	and	development	of	active	collaborations.19	Public	
scepticism	may	help	to	control	doctors'	dealings	with	industry,	
but	may	also	damage	the	doctor–patient	relationship.	
Physicians	need	to	be	aware	of	the	evidence	about	the	impact	
of	advertising	on	behaviour	and	community	perceptions.	While	
bans	on	the	provision	of	information	by	drug	companies	are	
inappropriate,	high	levels	of	critical	awareness,	supported	by	
educational	programs,	are	needed	by	clinicians.	
In	many	countries,	including	Australia,	the	purchase	of	
medications	is	heavily	subsidised	from	public	funds.	The	
prescriber	therefore	does	not	directly	bear	the	cost	of	their	
decisions.
Conflicts of interests
one	of	the	key	requirements	of	a	health	professional	involved	
in	interactions	with	industry	is	to	be	able	to	distinguish	dualities	
and	conflicts	of	interests.	A	duality	exists	where	there	are	two	or	
more	social	roles	that	overlap,	each	of	which	is	associated	with	
a	moral	imperative.	A	conflict	exists	where	these	imperatives	
are	contradictory	and	threaten	to	compromise	the	primary	goal	
of	one	of	them.	
A	duality	of	interest	would	exist	when	a	general	practitioner	
involved	in	research	is	considering	recruiting	their	own	patients	
for	a	study,	or	when	a	doctor	considers	accepting	travel	
assistance	from	a	pharmaceutical	company	to	attend	a	meeting	
with	undisputed	scientific	content	at	a	pleasant	resort	location.	
The	principles	for	responding	to	a	duality	are	straightforward.	
It	needs	to	be	identified	and	disclosed	publicly	to	the	relevant	
community.	This	community	should	decide	whether	it	
constitutes	a	conflict	and,	if	so,	this	needs	to	be	managed,	
usually	by	disengaging	the	two	conflicting	roles.	
Sometimes	this	process	of	disengagement	is	straightforward	
–	for	example,	if	researchers	propose	to	include	their	own	
patients	in	a	research	project	they	should	in	general	not	
approach	the	patient	themselves	but	leave	the	consent	process	
to	third	parties.	on	other	occasions,	such	as	where	a	researcher	
has	direct	pecuniary	interests	in	a	product	being	tested,	more	
elaborate	mechanisms,	such	as	an	arm's	length	committee	or	
divestment	of	shareholdings,	may	be	necessary.	
Regulation of drug promotion
In	response	to	the	real	or	perceived	risks	associated	with	the	
pharmaceutical	industry's	influence	and	power,	an	array	of	
formal	and	informal	mechanisms	for	regulating	the	industry	
has	developed.	These	include	rules	set	by	government,	
industry	codes	of	conduct,	guidelines	generated	by	practitioner	
associations,	processes	for	the	review	and	management	
of	research,	and	community	responses.	Together,	they	
seek	to	ensure	a	wide	range	of	goals,	including	protection	
of	the	interests	of	the	community	and	individual	patients,	
responsiveness	to	specific	clinical	contexts,	fostering	of	research	
and	development	of	new	products,	maintenance	of	public	
confidence	in	pharmaceuticals	and	medicine,	facilitation	of	
ethical	decision	making	among	the	various	participants,	and	
enhancement	of	options	and	freedom	to	act.	
Government
Although	government	regulation	undoubtedly	plays	a	key	
role,	it	is	a	blunt	instrument	that	may	not	be	able	to	provide	
specific	guidance	for	all	circumstances	that	occur	in	a	clinical	
setting.	Statutory	regulatory	regimes	are	also	cumbersome	and	
bureaucratic	and	require	elaborate	and	expensive	systems	of	
enforcement.	
Industry
The	industry	itself	has	developed	a	code	of	conduct,	which	
is	administered	through	the	industry	peak	body,	Medicines	
Australia.20	This	Code	has	been	criticised,	for	example,	on	
the	basis	that	membership	of	Medicines	Australia,	and	thus	
allegiance	to	its	policies,	is	voluntary	and	does	not	include	all	
manufacturers.	Areas	of	concern,	such	as	the	collection	and	
control	of	data,	are	omitted	altogether.	Enforcement	of	the	Code	
is	incomplete	and	mostly	relies	on	complaints.	Sanctions	for	
breaches	are	generally	modest.21	nonetheless,	it	is	believed	that	
the	Code	represents	a	substantial	achievement	and	that	it	has	
contributed	to	significant	change	in	the	commercial	behaviour	
of	the	pharmaceutical	industry	in	Australia.	For	example,	a	
recent	amendment	to	the	Code	now	requires	pharmaceutical	
companies	to	publicly	disclose	the	cost	of	events	organised	for	
doctors.
Guidelines for health professionals
A	number	of	professional	associations	have	developed	
guidelines	about	the	ethical	relationships	between	health	
professionals	and	the	pharmaceutical	industry.22,23	Among	these	
are	the	Royal	Australasian	College	of	Physicians	(RACP)24,	the	
Royal	Australian	College	of	General	Practitioners	(RACGP)25,	and	
the	Pharmaceutical	Society	of	Australia.26	
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RACP recommendations
These	guidelines	seek	to	demonstrate	how	dualities	may	
be	managed	in	specific	circumstances	that	arise	in	common	
practice.	They	recommend	that	gifts	should	be	rejected,	even	
items	of	trivial	value.	In	general,	acceptance	of	travel	expenses	is	
discouraged.	However,	where	a	practitioner	is	making	a	formal	
contribution	to	a	meeting	it	may	be	acceptable	for	the	organising	
committee	to	offer	assistance	with	travel	and	other	costs.
For	scientific	meetings	or	professional	development	events,	it	is	
important	that	programs	are	developed	by	committees	at	arm's	
length	from	sponsors	and	that	sponsorship	is	not	negotiated	on	
the	basis	of	conditions	relating	to	speakers	or	content.	
The	RACP	guidelines	cover	many	issues	regarding	research,	
including	design	of	experiments,	management	and	
interpretation	of	data,	and	publication	of	results,	which	raise	
the	possibility	of	conflicts	of	interests.	Researchers	have	special	
responsibilities	to	ensure	that	the	conduct	and	outcomes	of	
research	are	not	influenced	by	pecuniary	or	non-pecuniary	
interests	and	that	the	public	can	have	full	confidence	in	the	
integrity	of	any	data	that	are	disseminated.	
RACGP recommendations
The	RACGP	makes	similar	recommendations	to	general	
practitioners	but	is	more	relaxed	about	doctors	accepting	
gifts.	A	gift	may	be	accepted	but	the	patient	should	be	the	
primary	beneficiary	and	the	gift	should	be	related	to	the	general	
practitioner's	work.	So,	for	instance,	gifts	such	as	a	stethoscope	
or	a	textbook	are	acceptable,	whereas	gifts	of	a	holiday,	
frequent	flyer	points,	a	computer	or	cash	payments	are	not	
acceptable.	
The	guidelines	also	recommend	that	if	a	general	practitioner	
is	involved	in	postmarketing	surveillance	studies,	they	should	
make	it	clear	to	the	patient	that	the	patient's	welfare	is	not	
dependent	on	participation	in	the	study	and	they	can	withdraw	
at	any	time	and	start	an	alternative	treatment	if	they	wish.
The Pharmaceutical Society of Australia Code
Although	very	brief,	the	Code	obligates	pharmacists	to	avoid	
situations	that	may	present	a	conflict	of	interest.	Accepting	
inappropriate	gifts	is	also	contrary	to	the	Code.
Conclusion
opinions	differ	and	controversies	continue	about	the	influence	
of	the	pharmaceutical	industry	and	the	proper	responses	
to	it.	The	system	of	regulation	that	has	evolved	in	Australia	
is	complex	and	heterogeneous,	incorporating	components	
from	government,	industry,	community	and	the	professions.	
Although	each	would	on	its	own	be	insufficient,	together	
these	elements	constitute	a	delicately	balanced	equilibrium	
that	goes	at	least	some	way	towards	ensuring	that	the	diverse	
tasks	and	goals	set	by	the	various	stakeholders	are	addressed	
and	acknowledged.	Whether	the	balance	should	shift	more	in	
the	direction	of	regulation,	whether	a	more	punitive	approach	
would	be	more	or	less	effective,	how	best	to	maintain	both	
economic	incentives	and	public	responsibility	–	or	even	if	it	is	
possible	to	do	so	–	remains	uncertain.
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Dental notes
Prepared by Dr M McCullough of the Australian 
Dental Association
Relationships between health professionals 
and industry: maintaining a delicate balance
The	level	of	prescribing	that	occurs	in	the	average	dental	practice	
is	not	usually	such	that	it	attracts	the	attention	of	pharmaceutical	
companies'	marketing	departments.	However,	we	are	large	
consumers	of	restorative	materials,	medicaments	and	other	
products.	We	rely	on	a	good	working	relationship	with	dental	
supply	companies	who	not	only	offer	access	to	these	products,	
but	are	also	often	involved	in	research	related	to	them.	It	is	most	
likely	that	dentists	are	not	aware	of	the	influence	that	advertising,	
'special	offers',	personal	visits	by	company	representatives,	
endorsements	and	trade	shows	have	on	our	purchasing	habits.	
What	dental	practitioners	purchase	or	prescribe	should	always	
be	done	on	the	basis	of	available	scientific	evidence	with	
patients'	interest	utmost	in	our	minds.	In	fact,	in	the	majority	
of	practices	it	is	not	the	dentists	who	purchase	these	items,	but	
rather	the	practice	manager	on	the	advice	of	the	dentist,	advice	
that	may	not	be	consistently	available.	Situations	of	conflict	
and	duality	of	interest	may	well	be	relatively	common	in	the	
dental	profession,	and	these	should	be	acknowledged	and	
dealt	with	in	an	open	manner.		Currently,	the	Australian	Dental	
Association	is	developing	a	policy	to	advise	its	members	where	
these	conflicts	and	dualities	of	interests	arise.	
Medicines	Australia	has	a	Code	of	Conduct	to	guide	the	
promotion	of	prescription	drugs	by	pharmaceutical	companies	
in	Australia.	A	new	edition	of	the	Code	has	recently	been	
approved.1	Complaints	are	considered	by	the	Code	of	Conduct	
Committee	and	the	results	are	published	in	its	annual	report.	
The	report	for	2006–07	is	available	on	the	Medicines	Australia	
website.2	
This	year's	report	contains	detailed	information	about	41	
complaints.	In	fourteen	cases	no	breach	of	the	Code	was	found.	
Table	1	shows	the	27	complaints	in	which	at	least	one	breach	
of	the	Code	was	found.	As	usual,	most	of	the	complaints	were	
made	by	rival	pharmaceutical	companies,	but	12	were	made	by	
health	professionals.
Most	of	the	breaches	were	for	using	misleading	information	in	
promotional	material.	Some	of	the	larger	fines	were	imposed	
on	companies	that	had	allowed	the	public	to	be	exposed	
to	their	promotions.	Two	complaints	related	to	a	company	
which	sponsored	the	national	conference	of	a	patient	support	
Medicines Australia Code of Conduct: breaches 
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group.	An	article,	originally	drafted	for	health	professionals,	
but	published	in	Reader's	Digest,	clearly	breached	the	Code.	
Another	breach,	identified	by	several	complaints,	was	offering	
a	'money-back	guarantee'	to	patients	being	treated	for	erectile	
dysfunction.
The	information	in	the	report	reveals	some	of	the	sophisticated	
strategies	companies	can	use.	one	company	had	used	a	public	
relations	consultant	to	manage	a	campaign	about	a	medicine	
which	had	yet	to	be	approved	in	Australia.	This	included	
sponsoring	a	journalist	to	attend	an	overseas	conference	about	
the	drug.	Issuing	a	media	release	on	an	unapproved	drug	was	
considered	to	be	promotional	activity	which	breached	the	Code.	
The	Committee	had	to	grapple	with	what	constitutes	excessive	
The story of one complaint
John S Dowden, Editor
An	advertising	campaign	for	vardenafil	encouraged	men	
with	erection	difficulties	to	seek	treatment.	The	advertisement	
included	the	product	logo	and	the	name	of	the	company.	
The	imagery,	of	an	upright	banana,	was	also	used	in	the	
advertising	to	health	professionals.	As	part	of	this	parallel	
campaign,	doctors	and	pharmacists	were	informed	that	the	
company	would	offer	a	money-back	guarantee	to	patients.	
I	made	a	complaint	to	Medicines	Australia	as	I	believed	that	
the	advertising	to	the	public	would	stimulate	demand	for	a	
particular	product	and	the	money-back	guarantee	could	be	
seen	as	an	inducement.	Complaints	were	also	made	by	two	
pharmacists	and	the	Australian	Consumers'	Association.	
The	Code	of	Conduct	Committee	considered	my	complaint	
within	a	month	and	sent	me	its	decision	within	six	weeks.	The	
ruling	was	in	an	extract	of	the	minutes	of	the	Committee's	
meeting.	This	showed	that	there	had	been	a	severe	breach	
of	the	Code	of	Conduct,	but	I	was	asked	to	keep	the	ruling	
confidential	in	case	there	was	an	appeal.	As	there	was	no	
hospitality.	one	company	was	fined	for	providing	a	function	
that	was	not	'simple	or	modest',	while	a	function	at	the	Crown	
Towers	in	Melbourne	was	ruled	to	be	'not	extravagant'.	Perhaps	
the	new	requirement	for	companies	to	disclose	the	cost	of	their	
promotional	functions	will	help	the	Code	of	Conduct	Committee	
decide	what	is	appropriate.	
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appeal	the	complaint	was	finalised	and	details	appear	in	the	
Code	of	Conduct	Annual	Report.1
The	Code	of	Conduct	Committee	considered	that	the	
advertising	campaign	could	have	breached	nine	sections	of	the	
Code,	however	only	one	breach	was	confirmed.	A	majority	of	
the	Committee	considered	that	the	campaign	brought	discredit	
to	the	industry.	This	was	not	because	the	banana	images	
were	in	poor	taste,	but	because	a	money-back	guarantee	was	
considered	to	decrease	the	value	of	prescription	medicines.
The	Code	of	Conduct	Committee	did	not	fine	the	company	
for	the	severe	breach,	but	ordered	it	to	immediately	cease	
the	promotion	offering	the	money-back	guarantee.	Corrective	
letters	had	to	be	sent	to	all	health	professionals	who	received	
the	promotion	and	corrective	advertisements	had	to	be	
placed	in	health	professional	journals	which	had	published	
advertisements	about	the	money-back	guarantee.
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Table 1
breaches of the Code of Conduct July 2006 – June 2007
Company Drug Sanction imposed by Code of Conduct Committee
brand name generic name
Abbott	Australasia Lucrin	 leuprorelin	 Withdraw	material
Corrective	letter
$10	000	fine	
Alcon	Laboratories DuoTrav	 timolol	maleate/	
travoprost
Cease	program	
$10	000	fine
Allergan	Australia Lumigan	 bimatoprost Withdraw	material
Corrective	letter	
$15	000	fine
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AstraZeneca	 Crestor	 rosuvastatin	 Withdraw	promotional	materials		
Corrective	letter	
$75	000	fine	reduced	on	appeal	to	$40	000
nexium	 esomeprazole	 Withdraw	materials	
$75	000	fine
Bayer	Healthcare	 Levitra	
(four	complaints)
vardenafil Withdraw	money-back	guarantee	offer	
Corrective	letters	
Corrective	advertisement
Boehringer	Ingelheim Buscopan	 hyoscine	 Withdraw	material
$25	000	fine	reduced	on	appeal	to	$10	000
Mobic	 meloxicam Withdraw	materials	
Corrective	letter	
$25	000	fine
CSL	Limited	 Biostate	 factor	VIII $5000	fine	dropped	on	appeal
Behaviour	of	company	representative Withdraw	training	material
$15	000	fine
GlaxoSmithKline	
Australia
Rotarix	 rotavirus	vaccine	 Withdraw	materials	
Corrective	letter	
$25	000	fine
Tykerb	 lapatinib Provide	no	media	releases	until	medicine	registered	
$40	000	fine
Janssen-Cilag	 Pariet rabeprazole	 Withdraw	material	
$100	000	fine
Pariet	 rabeprazole	 Withdraw	material	
other	sanctions	covered	in	previous	breach
Merck	Sharp	&	Dohme Fosamax	Plus	 alendronate	 Withdraw	materials
octapharma	 octanate	 factor	VIII	 Withdraw	materials	
Corrective	letter	
$100	000	fine	reduced	on	appeal	to	$10	000
Pfizer	Australia	 Celebrex	 celecoxib Withdraw	materials	
$100	000	fine
Celebrex	 celecoxib	 Article	not	to	be	published	again	for	general	public	
$100	000	fine
Xalacom	 latanoprost/		
timolol	maleate
Withdraw	material	
Corrective	letter	
$50	000	fine
Roche	Products	 											Hospitality		 $75	000	fine
Sanofi-Aventis	 Stilnox	 zolpidem	 Withdraw	materials	
$5000	fine
Schering	 Betaferon	 interferon	beta-1b Withdraw	materials
Corrective	letters
$150	000	fine
Betaferon	 interferon	beta-1b Withdraw	materials
Letter	to	Multiple	Sclerosis	Society	
$100	000	fine
Angeliq	 drospirenone/	
oestradiol
Cease	distribution	of	trade	packs
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Treatment of myasthenia gravis
Stephen W Reddel, Sydney Neurology, Brain and Mind Research Institute,  
The University of Sydney, and Departments of Neurology and Molecular Medicine, 
Concord Repatriation General Hospital, Sydney
Summary
Myasthenia gravis is a syndrome of weakness 
and fatigue due to dysfunction of the 
neuromuscular junction. it is an antibody-
mediated autoimmune condition with a range 
of moderately effective treatments. occasionally 
patients go into remission spontaneously, but 
most require treatment. Mild disease, such 
as that confined to the ocular muscles, can 
often be treated with pyridostigmine alone. 
More significant or generalised weakness 
requires immunosuppression, principally with 
prednisone and azathioprine. The response 
to immunosuppression is slow, ranging from 
several months to 1–2 years for a full response. 
Short-term use of antibody-based therapy 
such as plasma exchange or intravenous 
immunoglobulin is warranted for more severely 
affected patients. Thymectomy offers the hope of 
drug-free remission but as yet remains unproven. 
Treatment-related morbidity is considerable, but 
partly preventable.
Key	words:	azathioprine,	immunosuppression,	prednisone,	
pyridostigmine,	thymectomy.
(Aust Prescr 2007;30:156–60)
introduction
Myasthenia	gravis	is	an	autoimmune	disease	which	causes	
muscular	weakness	due	to	dysfunction	of	the	neuromuscular	
junction	(Fig.	1).	Autoantibodies	directed	against	antigenic	
proteins	on	the	postsynaptic	side	of	the	neuromuscular	junction	
result	in	both	blockade	of	transmission	and	damage	to	the	
postsynaptic	structure.	As	a	result	the	motor	neuron	is	unable	
to	'talk'	to	the	muscle	fibre	and	weakness	results.	The	known	
antigens	to	which	the	autoantibodies	bind	are	the	acetylcholine	
receptor	and,	less	commonly,	muscle-specific	tyrosine	kinase.	
The	prevalence	of	myasthenia	gravis	is	about	1	in	10	000.	The	
gender	ratio	is	approximately	equal,	with	a	peak	incidence	of	
onset	in	the	20s	for	women	and	the	60s	for	men.	Around	10%	
of	patients	with	a	positive	acetylcholine	receptor	antibody	test	
have	an	associated	thymoma.	
Diagnosis
There	are	a	range	of	diagnostic	tests	for	myasthenia	
gravis.	These	include	dynamic	tests	for	measuring	muscle	
weakness	(for	example,	response	to	edrophonium	or	ice	
pack),	electrical	tests	such	as	repetitive	stimulation	or	single	
fibre	electromyography,	and	measurement	of	antibodies	to	
acetylcholine	receptor	and	to	muscle-specific	tyrosine	kinase.
Clinical manifestations
Myasthenia	gravis	affects	some	regional	muscles	more	than	
others.	Most	commonly	the	orbital	muscles	are	affected	first,	
with	either	diplopia	or	ptosis.	However,	myasthenia	gravis	may	
first	affect	the	bulbar	muscles	(speech	and	swallowing),	the	
neck	muscles	(head	drops)	and	proximal	or	rarely	distal	limb	or	
respiratory	muscles.	Involvement	is	fairly	symmetrical	except	
in	the	eyes.	Symptoms	may	get	worse	towards	the	end	of	the	
day	or	after	a	few	minutes	of	continuous	use	–	for	instance	
speech	may	become	slurred	over	a	few	minutes.	More	severe	
myasthenia	gravis	affects	multiple	muscular	regions	and	may	
be	sufficiently	severe	to	cause	respiratory	failure	and	death	if	
untreated.
Natural history of myasthenia gravis
Generally,	myasthenia	gravis	is	a	persistent	disease	requiring	
chronic	treatment.	Fluctuations	over	the	long	term	are	the	norm.	
Some	patients	go	into	long-term	remission	spontaneously	–	
approximately	15–25%	after	five	years	for	those	presenting	with	
generalised	disease	and	somewhat	more	for	those	presenting	
with	ocular	disease	only.	Late	relapse	after	sustained	remission	
also	occurs,	the	longest	reported	example	being	after	32	years.	
It	should	be	noted	that	the	neuromuscular	junction	can	be	
reformed,	unlike	many	parts	of	the	nervous	system.	Muscle	
strength	that	has	been	affected	by	myasthenia	gravis	for	a	long	
time	often	recovers	with	treatment.	This	means	that	the	intensity	
of	treatment	for	myasthenia	gravis	can	be	modulated	to	the	
current	severity	of	the	disease.	
over	time,	patients	with	clinically	isolated	ocular	myasthenia	
gravis	often	progress	to	generalised	myasthenia	gravis.	
Treatment	with	corticosteroids	can	reduce	the	likelihood	of	
progression,	and	control	both	ocular	and	generalised	weakness	
completely	in	many	cases.	It	is	not	known	if	this	alters	the	
natural	history	or	the	need	for	long-term	treatment.	It	is	
therefore	unclear	whether	treatment	should	be	commenced	for	
ocular	disease	or	just	'as	required'	to	control	symptoms	that	
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are	causing	sufficient	disability	to	justify	the	adverse	effects	of	
treatment.	Long-standing	ocular	misalignment	may	not	recover	
despite	generalised	remission.
Treatment 
The	diagnosis	must	be	confirmed	before	treatment,	because	the	
mainstay	of	treatment	for	most	patients	is	immunosuppression.	
Treatments	to	prevent	the	adverse	effects	of	
immunosuppression	should	be	started	simultaneously	with	the	
therapy	(see	Table	1).	There	is	no	robust	evidence	that	long-term	
treatment	actually	cures	the	condition,	so	some	patients	choose	
to	avoid	the	adverse	effects	of	immunosuppressive	therapy	
and	accept	degrees	of	weakness.	Coping	without	treatment	
is	not	always	the	safest	strategy	as	patients	with	significant	
weakness,	particularly	in	the	bulbar	musculature,	are	at	risk	
of	ventilatory	failure	or	of	needing	intensive	care	following	an	
intercurrent	respiratory	infection.	Immunosuppressive	treatment	
is	therefore	strongly	recommended	for	control	of	significant	
bulbar	weakness.	
Initial	treatment	is	usually	with	pyridostigmine,	followed	by	
prednisone	and	azathioprine	if	the	response	is	incomplete.	A	
combination	of	approaches	is	often	useful	to	cover	deficiencies	
in	each	available	drug.	
Immunosuppression	produces	a	very	slow	response,	often	
taking	many	months	to	1–2	years.1,2	An	unrealistic	expectation	
of	a	speedy	response	is	often	a	problem	for	both	the	patient	and	
the	doctor.	
There	are	four	main	approaches	to	treatment,	each	with	very	
different	durations	of	effect,	requirements,	consequences	and	
adverse	effects.
Improve neuromuscular transmission by 
inhibiting acetylcholinesterase 
Drugs	that	inhibit	acetylcholinesterase	include	pyridostigmine,	
edrophonium	(used	only	for	testing)	and	neostigmine	(for	
intravenous	use	in	intensive	care	units	only).	These	drugs	
take	effect	within	minutes	and	last	for	hours.	Although	they	
are	without	long-term	adverse	effects,	the	efficacy	of	all	
Fig. 1  
Normal muscular junction
In	the	normal	neuromuscular	junction,	acetylcholine	released	from	the	nerve	terminal	following	a	nerve	action	potential,	
binds	to	the	acetylcholine	receptor	on	the	postsynaptic	muscle,	triggering	a	muscle	action	potential	propagated	by	the	
voltage	gated	sodium	channel.	Acetylcholinesterase	scavenges	and	breaks	down	unbound	acetylcholine.	In	a	separate	
pathway,	neural	agrin	binds	muscle	specific	tyrosine	kinase	initiating	clustering	of	phosphorylated	rapsyn	and	acetylcholine	
receptors,	stabilising	the	postsynaptic	structure	opposite	the	nerve.
In	myasthenia	gravis	caused	by	antibodies	to	the	acetylcholine	receptor,	there	is	blockade	of	the	binding	site	for	
acetylcholine,	cross-linking	of	the	acetylcholine	receptor	with	subsequent	internalisation	and	reduction	in	its	surface	
expression,	and	initiation	of	complement	and	cellular	inflammatory	cascades	with	damage	to	the	post-	and	presynaptic	
structures.	The	molecular	physiology	of	myasthenia	gravis	mediated	by	antibodies	to	muscle	specific	tyrosine	kinase	has	
not	been	established.
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acetylcholinesterase	inhibitors	is	limited.	As	a	sole	drug	they	
are	not	enough	for	most	patients	with	generalised		
myasthenia	gravis.
Pyridostigmine
Pyridostigmine	is	the	first-line	treatment	for	myasthenia	
gravis.	It	is	a	reversible	inhibitor	of	acetylcholinesterase	
so	increases	acetylcholine	stimulation	of	the	remaining	
acetylcholine	receptors.	If	there	are	insufficient	acetylcholine	
receptors	remaining	to	trigger	a	muscle	action	potential,	extra	
acetylcholine	from	the	action	of	the	drug	is	not	going	to	help.	
The	underlying	autoimmune	state	is	not	altered.	It	is	often	
sufficient	for	ptosis	alone,	but	not	for	diplopia	or	generalised	
myasthenia	gravis.	Benefit	is	often	not	sustained,	possibly	due	
to	counterproductive	upregulation	of	acetylcholinesterase	and	
downregulation	of	acetylcholine	receptors.	The	dose	required	is	
variable,	as	is	gastrointestinal	tolerance.	one	approach	is	to	start	
at	10	mg	three	times	a	day	and	titrate	up	to	60	mg	4–6	times	
daily.	A	180	mg	'timespan'	preparation	is	available	for	nocturnal	
symptoms.	In	practice	a	degree	of	patient	control	of	dosing	and	
'when	required'	use	is	often	helpful.
Doses	less	than	480	mg	daily	rarely	produce	depolarising	crisis.	
Increasing	weakness	after	an	increase	in	the	pyridostigmine	
dose	(when	high	doses	are	already	being	given)	suggests	
deteriorating	disease	and/or	a	depolarising	crisis.	This	may	
require	treatments	such	as	plasma	exchange	and	a	reduction	in	
pyridostigmine	dose.	The	presence	of	gastrointestinal	adverse	
effects	and	fasciculations,	clinically	or	on	electromyogram,	
might	suggest	depolarising	crisis.	The	patient	must	be	
hospitalised	and	the	dose	of	pyridostigmine	reduced	while	
they	are	carefully	monitored.	Lack	of	improvement	with	
edrophonium	(which	has	a	very	short	half-life)	indicates	that	
further	pyridostigmine	will	not	be	useful.	
Immunosuppression
The	principal	drugs	used	to	suppress	the	immune	system	
in	myasthenia	gravis	are	prednisone	(a	glucocorticoid)	and	
azathioprine.	The	response	to	these	treatments	can	take	weeks	to	
many	months,	with	the	maximal	effect	taking	months	to	years.1,2
Prednisone
Prednisone	or	another	corticosteroid	is	the	primary	
immunosuppressant	used	in	myasthenia	gravis.	Sustained	
improvement	or	remission	can	be	achieved	while	patients	
remain	on	treatment.	A	typical	course	for	generalised	
myasthenia	gravis	would	use	1	mg/kg	prednisone	daily		
(0.5	mg/kg	for	ocular	myasthenia	gravis)	until	clinical	control	
is	achieved	and	then	weaning	either	directly	or	by	initial	
conversion	to	alternate	daily	dosage,	with	the	determination	of	
a	maintenance	dose	by	trial	and	error	during	a	slow	withdrawal	
of	medication	over	many	months.	Deterioration	in	myasthenia	
gravis	can	occur	in	the	first	few	weeks	of	treatment	so	the	dose	
is	often	increased	slowly.	The	mean	time	to	maximal	effect	of	
prednisone	in	myasthenia	gravis	is	six	months	–	much	longer	
than	most	expect.
Azathioprine
Azathioprine	is	used	as	a	steroid	sparing	drug	and	additional	
immunosuppressant	with	prednisone.	In	a	randomised	trial,	
after	three	years	of	treatment,	63%	of	patients	with	myasthenia	
gravis	taking	azathioprine	were	off	all	prednisone,	versus	
20%	taking	placebo,	but	no	effect	was	seen	in	the	first	year.2	
Compared	to	the	metabolic	consequences	of	continued	
corticosteroids,	the	problems	of	azathioprine	seem	significantly	
less.	However,	the	long-term	consequences	do	include	an	
increased	risk	of	skin	cancers	and	a	small	possible	increase	
in	the	risk	of	haematological	malignancies.	About	one-fifth	
Table 1
Prophylaxis of the complications of immunosuppression
osteoporosis	prevention Measure	bone	density	before	treatment	and	yearly	while	on	treatment.	Start	calcium	and	
vitamin	D	supplements.	Bisphosphonates	may	reduce	bone	loss	associated	with	the	chronic	
use	of	glucocorticoids.	
Cardiovascular	risk Risk	factor	modification	should	be	standard	and	includes	advice	to	stop	smoking,	start	an	
exercise	program	and	manage	hypertension.	
Peptic	ulcer	prevention Helicobacter	screening	and	prophylactic	treatment	with	proton	pump	inhibitors	or	H2	
antagonists	seems	appropriate	for	those	with	a	past	history	of	previous	ulceration	or	
concordant	use	of	non-steroidal	anti-inflammatory	drugs.
Infection	prophylaxis Use	of	inactivated	vaccines	such	as	influenza	is	recommended.	Live	vaccines	are	
contraindicated.	A	chest	X-ray	should	be	performed	prior	to	treatment.	More	specific	testing	for	
tuberculosis	may	be	indicated	depending	on	history	and	chest	X-ray	results.
Malignancy	prevention Skin	cancer	rates	are	increased	in	patients	using	azathioprine.	A	full	yearly	dermatological	
survey	is	recommended.	Exhort	sun	protection	and	cancer	surveillance.	Regular	cervical	smears	
are	recommended.	Eye	protection	may	also	limit	cataract	development.	
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of	patients	cannot	take	azathioprine	due	to	rash,	hepatitis,	
myelosuppression,	nausea	or	vomiting,	but	this	is	usually	
evident	within	two	weeks	to	two	months.	Some	doctors	
routinely	use	azathioprine	for	patients	with	generalised	
myasthenia	gravis	still	requiring	more	than	10	mg	prednisone	
per	day	at	six	months,	or	if	severe	disease	is	obvious	earlier.	
Other drugs
If	not	using	azathioprine,	other	steroid-sparing	drugs	used	
include	mycophenolate	mofetil,	cyclosporin,	methotrexate	and	
cyclophosphamide.	Experience	with	these	drugs	is	generally	
derived	from	retrospective	series.	none	of	these	have	proven	
efficacy	in	randomised	trials	except	for	cyclophosphamide,	and	
choice	of	drug	depends	on	age	and	competency	of	the	patient	
plus	local	experience	of	the	physician.	In	practice	they	are	
frequently	used	with	apparent	success,	but	like	azathioprine	the	
response	is	often	slow.
Mycophenolate	mofetil	is	a	pharmacologically	similar	
alternative	to	azathioprine	but	two	recent	randomised	controlled	
trials	failed	to	demonstrate	benefit	in	myasthenia	gravis.*	The	
duration	of	both	trials	was	less	than	a	year.	As	it	works	in	the	
same	pathway	as	azathioprine	this	may	have	been	inadequate	
and	it	remains	widely	used.	
Rituximab,	a	monoclonal	antibody	specific	to	CD20	(on	B	cells),	
or	bone	marrow	ablation	with	autologous	transplant	are	
treatments	of	last	resort.
Remove or block autoantibodies 
Plasma	exchange	removes	autoantibodies	and	intravenous	
immunoglobulin	is	thought	to	block	autoantibodies.	These	
treatments	take	effect	within	days,	but	only	last	weeks	before	
treatment	needs	to	be	repeated.	They	have	a	key	role	in	
stabilising	severe	myasthenia	gravis	and	in	preparation	for	
surgery,	or	in	pregnancy.	
Plasma	exchange	is	expensive	and	only	available	in	major	
hospitals.	It	requires	good	intravenous	or	alternatively	central	
catheter	access,	but	a	central	line	increases	the	risk	of	infection.	
Intravenous	immunoglobulin,	a	purified	blood	product,	is	also	
very	expensive	and	is	in	limited	supply.	Its	mode	of	action	
remains	unclear.
Thymectomy
Thymectomy	has	a	possible	immunomodulatory	role	in	the	
absence	of	thymoma.	Results	of	a	global	randomised	trial	
are	awaited.†	The	effect	of	a	thymectomy	appears	to	take	
years.	non-randomised	retrospective	data	suggest	there	is	an	
increased	complete	remission	rate	from	thymectomy	when	
it	is	performed	within	2–3	years	of	the	onset	of	disease.	This	
treatment	involves	major	surgery	with	midline	sternotomy,	
although	minimally	invasive	approaches	are	becoming	
available.	other	than	surgical	complications	there	are	no	known	
long-term	adverse	effects.
Thymectomy	for	thymoma	does	not	on	average	improve	
myasthenia	gravis,	but	is	required	to	remove	the	tumour.
Drugs that worsen myasthenia gravis
neuromuscular	blocking	drugs	used	for	intubation	and	
muscle	relaxation	in	surgery	cause	profound	deterioration	in	
myasthenia	gravis	with	marked	prolongation	and	severity	of	
neuromuscular	dysfunction.	The	diagnosis	of	myasthenia	gravis	
should	be	considered	if	patients	fail	to	breathe	spontaneously	or	
are	weak	after	an	anaesthetic.
Aminoglycosides	such	as	gentamicin	partially	block	the	
neuromuscular	junction	and	dramatically	worsen	myasthenia	
gravis.	Beta	blockers	have	a	generally	mild	adverse	effect	
(adrenergic	stimulus	is	mildly	beneficial	for	myasthenia	gravis)	
and	the	need	to	use	them	should	be	carefully	considered.	
Anticholinergics	of	all	types	logically	have	a	deleterious	effect	
on	the	neuromuscular	junction.	In	practice	a	muscarinic	
anticholinergic	such	as	propantheline	is	sometimes	used	
to	control	the	adverse	effects	of	pyridostigmine	on	the	gut.	
Many	other	drugs	have	been	cited	as	provoking	deterioration	
in	myasthenia	gravis	or	have	myasthenia	gravis	listed	as	
a	contraindication	to	use	in	the	product	information.	This	
includes	tetracyclines	and	quinolones,	which	in	practice	are	
only	occasionally	problematic.	Sedatives	such	as	narcotics	and	
benzodiazepines	have	no	direct	effect	on	the	neuromuscular	
junction	but	obviously	are	contraindicated	if	hypercapnia	or	
respiratory	failure	are	a	risk.
Conclusion
Myasthenia	gravis	is	a	readily	treatable	condition	and	many	
patients	can	expect	to	have	little	disability.	It	should	be	
acknowledged	that	of	the	residual	disability,	a	considerable	
amount	comes	from	the	treatment.	Attempts	to	re-establish	
immune	tolerance	of	the	acetylcholine	receptor	to	cure	the	
condition	have	not	yet	borne	fruit.	no	revolution	in	treatment	is	
expected	in	the	near	future.
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Dental notes
Prepared by Dr M McCullough of the Australian 
Dental Association
Treatment of myasthenia gravis
The	prevalence	of	myasthenia	gravis	(about	1	in	10	000	people)	
is	such	that	every	dentist	will	probably	treat	more	than	one	
patient	with	the	condition	during	their	career.	Changes	in	
tongue	and	facial	muscle	strength	can	often	be	the	first	sign	of	
myasthenia	gravis.	These	changes	may	impact	on	oral	hygiene	
and	the	ability	to	wear	dentures.	Postural	changes	and	the	
potential	for	the	patient's	medication	to	interact	with	drugs	
given	by	the	dentist	means	that	patients	with	myasthenia	gravis	
have	specific	needs	during	dental	treatment.	
A	review	of	the	dental	literature	recommended	that,	depending	
on	the	severity	of	disease,	patients	should	have	multiple,	
short,	early	morning	appointments,	perhaps	preceded	by	
oral	anticholinesterase	drugs,	to	take	advantage	of	their	early	
morning	muscle	strength.1	Factors	related	to	dental	treatment	
that	are	likely	to	worsen	myasthenia	gravis	should	be	avoided,	
such	as	stressful	protracted	procedures,	the	use	of	ester-linked	
local	anaesthetics	(not	available	in	Australia)	and	the	use	
of	antibiotics	that	have	some	muscle	relaxing	properties	
(erythromycin,	gentamicin,	neomycin	and	clindamycin).1	The	use	
of	these	drugs,	as	well	as	the	use	of	benzodiazepines,	sedation	
and	general	anaesthesia,	has	been	reported	to	worsen	muscle	
weakness	and	should	only	be	undertaken	after	consultation	with	
the	patient's	physician.	To	avoid	complications,	dentists	should	
therefore	have	good	communication	not	only	with	the	patient,	
but	also	with	the	treating	physician.
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Patient support organisation
Australian Myasthenic Association in NSw
The	Australian	Myasthenic	Association	in	nSW	was	set	up	to	
support	sufferers	of	myasthenia	gravis	and	their	carers.	It	has	
members	from	all	over	Australia	and	overseas.
The	website	contains	useful	information	about	myasthenia	
gravis,	its	causes,	symptoms,	diagnosis,	treatments	and	history.	
There	are	links	to	a	range	of	patient	support	resources	such	
as	newsletters,	chat	facilities,	events,	patient	experiences	and	
practical	lifestyle	advice.	A	membership	fee	entitles	members	to	
receive	the	association's	newsletters	and	goes	towards	funding	
events	and	other	costs.	
Website:		www.myasthenia.org.au
Email:		 info@myasthenia.org.au
Phone:		 (02)	4283	2815	
Address:	108	Bantry	Bay	Road	
	 FREnCHS	FoREST	nSW	2086
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Myasthenia gravis: a patient's perspective
Mark	Latham	was	the	United	nations	representative	in	the	
Cape	Verde	Islands.	He	was	56	years	old	when	he	developed	
myasthenia	gravis	in	1998.
AP:	 What were the first symptoms you had?
ML:	 I	had	some	back	pain	due	to	all	the	packing	and	unpacking	
I	do	on	my	travels,	but	then	I	began	to	feel	weaker.	The	
orthopaedic	opinion	was	that	I	had	a	disc	problem	and	I	
was	advised	to	rest	in	bed.
	 During	this	period	of	bed	rest	I	noticed	my	arms	were	
weak.	It	was	difficult	to	hold	a	book	to	read.	over	the	next	
few	weeks	I	experienced	some	difficulty	chewing	and	
swallowing.
AP:	 How was the diagnosis made?
ML:	 I	had	to	travel	to	the	Un	headquarters	in	new	York,	but	I	
was	so	weak	I	had	to	do	the	whole	journey	on	a	stretcher.	
When	I	got	to	the	USA	I	was	taken	by	ambulance	to	
the	emergency	department	of	a	large	city	hospital.	My	
wife	suggested	that	I	had	a	neurological	problem	so	a	
neurologist	was	called	to	see	me.	He	quickly	diagnosed	
myasthenia	gravis	and	confirmed	this	by	giving	me	an	
injection	which	promptly	improved	how	I	felt.
AP:	 How did you feel about the diagnosis?
ML:	 Myasthenia	gravis	did	not	mean	anything	to	me,	but	I	was	
glad	that	somebody	now	knew	what	was	wrong	with	me.
AP:	 What treatment were you given?
ML:	 I	was	given	prednisone	and	pyridostigmine.	Within	a	
week	I	was	walking,	but	then	I	began	to	feel	worse.	I	then	
collapsed.	I	was	paralysed	and	only	able	to	move	my	
wrist	and	head.	It	was	hard	to	breathe.	I	was	admitted	to	
intensive	care	and	had	three	hours	of	plasmapheresis	
every	other	day	for	seven	sessions.	This	had	to	be	done	
through	a	femoral	tap.
	 Azathioprine	was	added	to	my	treatment	and	I	gradually	
improved.	Being	able	to	sit	up	and	turn	myself	over	in	bed	
were	big	achievements.	While	I	was	in	new	York	I	had	my	
thymus	removed.
AP:	 How were you able to get around?
ML:	 I	lost	a	lot	of	muscle	so	I	had	to	learn	to	walk	again.	When		
I	was	discharged	from	hospital	I	was	in	a	wheelchair.		
I	stayed	in	a	hotel	for	a	month	and	just	had	to	practise	
walking	up	and	down	the	corridor,	first	with	a	frame	and	
then	with	a	stick.	I	had	physiotherapy	three	times	a	week.
	 Going	out	of	the	hotel	was	difficult.	I	could	not	lift	my	feet	
over	the	smallest	step	and	I	fell	over	several	times.	When	I	
went	to	hospital	by	taxi	I	was	unable	to	get	out	of	my	seat.
AP:	 Were you able to work?
ML:	 When	I	returned	to	the	Cape	Verde	Islands	I	waited	a	
month	to	build	up	my	strength	before	resuming	work.
	 Back	at	work	I	found	that	I	was	easily	fatigued.	I	could	only	
sit	in	meetings	for	an	hour.	Having	a	chair	with	a	high	back	
helped	to	support	my	head.
AP:	 Have you had any relapses?
ML:	 About	six	months	after	returning	to	the	Cape	Verde	Islands	
I	started	feeling	increasingly	weak	particularly	in	the	legs	
and	neck.	My	eyelids	started	to	droop	and	my	breathing	
became	laboured.
	 This	time	I	was	treated	in	oxford,	England.	By	the	time	
I	got	there	my	eyelids	were	completely	closed	and	
breathing	was	very	difficult.	My	eyes	stayed	shut	for	
six	weeks.	The	pyridostigmine	and	azathioprine	were	
continued	and	the	prednisone	was	increased.	I	also	had	
plasmapheresis	and	I	gradually	recovered.
	 I	retired	to	Sydney	in	2000	and	had	one	recurrence	of	
weakness	in	2002	when	I	experienced	double	vision.	This	
was	managed	with	plasmapheresis.
AP:	 Have you had any side effects from your treatment?
ML:	 The	pyridostigmine	gives	me	nausea	and	a	headache.	I	had	
to	have	cataracts	removed	from	both	eyes	as	a	result	of	the	
prednisone.	I	have	also	had	a	few	skin	cancers	removed	
and	now	take	mycophenolate	in	place	of	azathioprine.
AP:	 How are you managing now?
ML:	 My	weakness	can	vary	from	day	to	day.	on	some	days	I	
can	walk	five	kilometres,	on	others	I	can	barely	manage	
one	kilometre.	I	am	unable	to	run.
I	am	able	to	drive	again,	but	manual	transmission	was	a	
problem.	In	a	traffic	jam	my	left	leg	ran	out	of	strength		
and	I	was	unable	to	move	the	clutch	pedal.	I	now	drive		
an	automatic.
The	main	problem	now	is	fatiguability.	I've	retired,	so	the	
fatigue	is	manageable	and	does	not	interfere	with		
my	lifestyle.
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Antipsychotic drugs in pregnancy and 
breastfeeding
Debra Kennedy, Director, MotherSafe, Royal Hospital for Women, and Conjoint Lecturer, 
School of Women’s and Children’s Health, University of New South Wales, Sydney
Summary
There are limited data on the safety of 
antipsychotic drugs in pregnancy and 
breastfeeding. Reports of congenital 
abnormalities in the babies of women taking 
typical antipsychotics are uncommon, although 
chlorpromazine may cause symptoms in 
the neonate. No increased risk with atypical 
antipsychotics has yet emerged. if women 
can be managed with a low dose of a single 
antipsychotic drug the benefits of breastfeeding 
are likely to outweigh the risk of harmful effects.
Key	words:	chlorpromazine,	olanzapine.
(Aust Prescr 2007;30:162–3)
introduction
The	lifetime	prevalence	of	schizophrenia	is	0.5–1%.	The	peak	
incidence	in	women	is	during	their	childbearing	years,	but	
treatment	can	reduce	fertility.	The	older	antipsychotic	drugs	
increase	prolactin,	resulting	in	significantly	lower	fertility	
rates	than	with	the	atypical	antipsychotic	drugs.	The	newer	
antipsychotics	are	also	being	used	increasingly	to	treat	other	
psychiatric	disorders	such	as	major	depression	and	bipolar	
disorder.	Many	women	with	well-controlled	psychiatric	disease	
are	therefore	now	able	to	contemplate	pregnancy,	but	they	
have	concerns	about	the	effect	of	treatment	on	their	offspring.	
Addressing	these	concerns	is	difficult	because	of	a	lack	of	data.	
Typical antipsychotic drugs
Studies	examining	the	use	of	the	older	antipsychotic	drugs	in	
pregnancy	have	not	shown	a	significantly	increased	risk	of	birth	
defects	above	the	baseline	rate	of	3%	in	the	general	population.1	
There	have	been	reports	of	two	infants	exposed	to	haloperidol	
with	isolated	limb	defects,	but	they	were	also	exposed	to	
other	drugs	and	thus	there	is	no	clear	causal	relationship	with	
haloperidol.	In	contrast,	there	have	been	several	larger	studies	
which	have	not	shown	an	increased	risk	of	birth	defects.	Babies	
exposed	to	haloperidol	and	chlorpromazine	in utero	may	show	
extrapyramidal	abnormalities,	similar	to	those	seen	in	adults,	
for	weeks	after	birth.	other	suspected	withdrawal	symptoms	
following	intrauterine	exposure	to	chlorpromazine	have	
included	paralytic	ileus,	necrotising	enterocolitis,	fever,	cyanotic	
spells	and	transient	heart	block.
Long-term	follow-up	studies	of	children	have	been	reassuring.	
While	these	drugs	probably	still	have	their	place	in	the	
treatment	of	acutely	psychotic	patients,	they	have	largely	
been	superseded	by	the	atypical	antipsychotics	for	long-term	
therapy.2,3
Flupenthixol	and	the	depot	preparation	zuclopenthixol	are	
thioxanthene	major	tranquillisers.	There	are	minimal	human	
data	apart	from	some	case	reports	of	normal	outcomes	
following	use	in	pregnancy.	Like	the	older	antipsychotic	drugs	
they	have	been	shown	to	affect	fertility	via	dopamine	and	
prolactin	pathways.
Lactation
Chlorpromazine	and	haloperidol	are	excreted	in	human	
milk	in	small	amounts.	In	one	report,	three	breastfed	
infants	exposed	to	haloperidol	and	chlorpromazine	showed	
developmental	regression	which	was	not	seen	in	infants	
exposed	to	trifluoperazine	alone,	suggesting	that	use	of	a	single	
antipsychotic	drug	poses	less	of	a	risk	to	a	breastfed	infant.	
no	adverse	effects	were	reported	in	four	infants	exposed	to	
flupenthixol	via	breast	milk.
Atypical antipsychotic drugs
one	study	followed	up	over	150	cases	of	exposure	to	atypical	
antipsychotic	drugs	(olanzapine,	risperidone,	quetiapine	and	
clozapine)	in	the	first	trimester	of	pregnancy.	There	were	no	
differences	in	any	of	the	pregnancy	outcomes	of	interest,	apart	
from	low	birth	weight,	which	could	not	be	explained	by	the	
study's	authors.	The	rate	of	malformations	in	the	exposed	group	
was	no	greater	than	in	the	control	group.4	
Animal	studies	have	not	shown	an	increased	risk	of	
malformations	with	clozapine.	Although	human	pregnancy	
data	are	relatively	limited,	there	does	not	appear	to	be	a	
significant	increase	in	the	incidence	of	birth	defects	or	other	
adverse	outcomes.	There	is	one	case	report	of	a	child	with	
possible	delayed	speech	acquisition	following	clozapine	
use	during	pregnancy	and	lactation.5	no	other	long-term	
neurodevelopmental	follow-up	data	are	available.
Concerns	have	been	raised	that	olanzapine	in	particular	
tends	to	be	associated	with	significant	weight	gain.	During	
pregnancy	this	could	be	associated	with	an	increased	incidence	
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of	outcomes,	including	increased	rates	for	birth	defects	such	
as	neural	tube	defects	and	an	increased	risk	of	obstetric	
complications.	Theoretical	concerns	about	a	relative	folate	
deficiency	have	prompted	some	experts	to	suggest	that	women	
planning	pregnancy	while	taking	olanzapine	should	take	5	mg	
folate	rather	than	the	usual	0.5	mg	to	try	and	reduce	the	risk	of	
neurodevelopmental	disabilities.6
Lactation
Limited	information	shows	that	maternal	doses	of	olanzapine	
up	to	20	mg/day	produce	low	levels	in	milk	and	undetectable	
levels	in	breastfed	infants.	Generally,	short-term	adverse	effects	
have	not	occurred,	and	sedation	has	not	been	reported.	Limited	
long-term	follow-up	of	infants	exposed	to	olanzapine	has	been	
reassuring,	particularly	with	monotherapy.	
Conclusion
The	potentially	harmful	effects	of	taking	an	antipsychotic	drug	
in	pregnancy	have	to	be	balanced	against	the	harm	of	untreated	
psychotic	illness.	Data	are	limited,	particularly	for	the	atypical	
antipsychotic	drugs,	but	there	are	no	clear	associations	with	
specific	congenital	abnormalities.
The	benefits	of	breastfeeding	are	likely	to	outweigh	the	potential	
harm	of	medication.	Women	who	wish	to	breastfeed	should	
be	managed	with	a	single	antipsychotic	drug	if	possible.	All	
antipsychotic	drugs	are	sedating	and	have	relatively	long	half-
lives,	so	babies	should	be	observed	for	lethargy,	sedation	and	
appropriate	developmental	milestones	particularly	if	multiple	
antipsychotic	drugs	are	used.	
note:	A	national	register	of	antipsychotic	medication	in	
pregnancy	has	been	developed.	For	information	phone		
(03)	9076	6988	or	email	H.Gilbert@alfred.org.au
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New drugs
Some	of	the	views	expressed	in	the	following	notes	on	newly	approved	products	should	be	regarded	as	tentative,	as	there	may	have	been	little	
experience	in	Australia	of	their	safety	or	efficacy.	However,	the	Editorial	Executive	Committee	believes	that	comments	made	in	good	faith	at	an	early	
stage	may	still	be	of	value.	As	a	result	of	fuller	experience,	initial	comments	may	need	to	be	modified.	The	Committee	is	prepared	to	do	this.	Before	
new	drugs	are	prescribed,	the	Committee	believes	it	is	important	that	full	information	is	obtained	either	from	the	manufacturer's	approved	product	
information,	a	drug	information	centre	or	some	other	appropriate	source.
Abatacept
orencia	(Bristol-Myers	Squibb)
vials	containing	250	mg	lyophilised	powder	
Approved	indication:	rheumatoid	arthritis
Australian	Medicines	Handbook	section	15.2
The	primary	goal	of	treatment	for	rheumatoid	arthritis	is	to	
preserve	and	restore	physical	function	as	well	as	modify	the	
disease	process	and	slow	down	the	development	of	joint	
damage.	In	Australia,	methotrexate	is	initially	used	to	manage	
the	disease.	It	is	often	given	with	other	disease-modifying	
antirheumatic	drugs	(DMARDs)	for	moderate	to	severe	disease	
(Aust	Prescr	2003;26:36–40).	If	these	drugs	are	not	effective	or	
not	tolerated,	biological	agents	such	as	tumour	necrosis	factor	
(TnF)	inhibitors	may	be	considered.	
Abatacept,	a	genetically-engineered	protein,	is	a	biological	
drug	for	rheumatoid	arthritis	which	is	designed	to	suppress	
T	cell-mediated	inflammatory	reactions.	It	is	made	up	of	
the	extracellular	part	of	the	human	cytotoxic	lymphocyte-
associated	antigen	(CTLA-4)	linked	to	a	fragment	of	human	
immunoglobulin	G.	Abatacept	works	by	binding	to	two	signal	
molecules	(CD80	and	CD86)	on	antigen-presenting	cells,	thereby	
preventing	them	from	activating	T	cells.	
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Abatacept	should	be	given	as	a	30-minute	intravenous	
infusion.	The	dose	is	dependent	on	the	patient's	body	weight.	
The	infusion	should	be	repeated	at	two	and	four	weeks	and	
then	every	four	weeks	after	that.	Following	multiple	10	mg/kg	
intravenous	infusions	of	abatacept,	the	serum	concentration	
reaches	a	steady	state	after	60	days.	The	mean	half-life	is	
approximately	13	days	in	patients	with	rheumatoid	arthritis,		
and	clearance	increases	with	body	weight.	
When	given	as	a	monotherapy	to	patients	with	severe	active	
rheumatoid	arthritis,	more	patients	responded	to	abatacept	
(10	mg/kg)	than	to	placebo.	After	85	days,	a	20%	clinical	
improvement	(based	on	the	criteria	of	the	American	College	of	
Rheumatology)	was	observed	in	53%	of	patients	on	abatacept	
compared	with	31%	on	placebo.1	This	study	was	primarily	a	
dose-finding	trial	and	so	there	were	only	32	patients	in	the	
abatacept	10	mg/kg	group.	
Abatacept	appears	to	be	efficacious	when	given	in	combination	
with	other	DMARDs.2,3,4,5,6	In	a	trial	of	patients	with	active	
disease	despite	methotrexate,	652	patients	were	randomised	to	
also	receive	abatacept	or	placebo.	After	a	year,	73%	of	patients	
given	abatacept	had	a	20%	clinical	improvement	compared	to	
only	40%	of	those	given	placebo.	There	was	slower	radiological	
progression	of	joint	damage	in	the	abatacept	group.4	
In	another	trial	patients	who	had	not	responded	to	anti-TnF	
therapy	received	either	abatacept	or	placebo	with	another	
DMARD.	More	patients	in	the	abatacept	group	than	in	the	
control	group	had	a	20%	improvement	(50%	vs	20%	of	patients	
after	six	months).	However,	reduced	progression	of	joint	
damage	was	not	established	in	these	patients.5	
Infusion-related	reactions,	such	as	dizziness	and	headache,	
are	common	with	abatacept.	In	a	one-year	safety	trial	of	
1441	patients,	serious	infections	were	more	frequent	with	
abatacept	than	with	placebo	(2.9%	vs	1.9%).	Pneumonia	
was	the	most	common	type	of	serious	infection.	In	patients	
receiving	other	biological	drugs	as	well	as	abatacept,	the	rate	
of	serious	infections	increased	to	5.8%.	overall,	the	incidence	
of	neoplasms	was	similar	with	abatacept	compared	to	placebo	
(3.5%).	However,	this	rate	increased	to	6.8%	in	patients	who	
were	also	taking	other	biological	drugs.	In	patients	with	chronic	
obstructive	pulmonary	disease,	there	were	more	adverse	events	
with	abatacept	than	with	placebo.7
As	abatacept	inhibits	T	cell	activation,	it	may	affect	a	patient's	
ability	to	fight	infections	or	malignancies.	Caution	is	needed	
when	treating	patients	who	have	a	history	of	recurrent	
infections	and	patients	should	be	checked	for	latent	tuberculosis	
infections	and	viral	hepatitis	before	starting	treatment.	Live	
vaccines	should	be	avoided.	
Abatacept	in	combination	with	methotrexate	is	indicated	for	
patients	with	moderate	to	severe	rheumatoid	arthritis	who	have	
had	an	inadequate	response	or	intolerance	to	other	DMARDs.	
non-biological	DMARDs	can	be	used	with	abatacept,	however,	it	
should	not	be	given	with	biological	drugs	such	as	adalimumab,	
anakinra,	etanercept	and	infliximab.	
As	rare	but	potentially	fatal	adverse	effects	can	occur	with	
abatacept,	longer-term	safety	studies	are	needed.	It	is	not	known	
how	abatacept	compares	with	other	treatments	for	rheumatoid	
arthritis	as	there	do	not	appear	to	be	any	comparative	studies.
	 manufacturer	provided	clinical	evaluation
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Exenatide
Byetta	(Eli	Lilly)
250	microgram/mL	in	1.2	mL	and	2.4	mL	pre-filled	pen	injectors
Approved	indication:	type	2	diabetes
Australian	Medicines	Handbook	section	10.1.4
An	oral	dose	of	glucose	causes	more	insulin	secretion	than	
the	same	dose	given	intravenously.	This	is	because	glucose	
in	the	gut	stimulates	the	release	of	hormones	called	incretins	
which	increase	insulin	secretion.	As	this	action	would	have	a	
favourable	effect	in	diabetes	researchers	have	tried	to	develop	
drugs	with	a	similar	action.
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one	of	the	incretins	is	a	glucagon-like	peptide	(GLP-1).	The	venom	
of	a	lizard	(Heloderma suspectum)	contains	a	peptide	with	a	
similar	structure	and	this	led	to	the	development	of	exenatide,	an	
injectable	synthetic	peptide	that	acts	as	a	GLP-1	agonist.
Unlike	GLP-1,	exenatide	is	not	rapidly	inactivated.	Instead	
it	is	cleared	by	the	kidneys	at	a	rate	which	enables	twice-
daily	dosing.	Plasma	concentrations	peak	two	hours	after	a	
subcutaneous	injection	so	exenatide	should	be	injected	before	
morning	and	evening	meals.	
Postprandial	and	fasting	glucose	concentrations	are	reduced	by	
exenatide.	It	also	moderates	glucagon	secretion,	slows	gastric	
emptying	and	decreases	appetite.
A	28-day	study	investigated	different	regimens	of	exenatide	in	
patients	being	treated	for	type	2	diabetes.	Compared	to	the		
28	patients	randomised	to	receive	placebo,	the	81	patients	
injecting	exenatide	had	significantly	greater	reductions	in	
glycated	haemoglobin	(HbA1c).1
A	longer-term	study	looked	at	adding	exenatide	to	the		
treatment	of	patients	whose	diabetes	was	not	controlled	by	
the	maximum	dose	of	sulfonylureas.	Placebo	injections	were	
given	to	123	patients,	while	125	injected	exenatide	5	microgram	
and	129	injected	10	microgram.	All	injections	were	given	twice	
daily.	At	the	start	of	the	study	the	HbA1c	averaged	8.6%.	In	the	
30th	week	of	the	trial	this	had	fallen	by	0.46%	with	exenatide	
5	microgram	and	by	0.86%	with	10	microgram.	In	the	placebo	
group	HbA1c	increased.2	
A	similar	study	compared	the	two	doses	of	exenatide	with	
placebo	in	336	patients	taking	at	least	1.5	g	metformin	daily.	
After	30	weeks	HbA1c	had	declined	by	0.4%	with	5	microgram	
exenatide,	0.78%	with	10	microgram,	while	it	had	increased	in	
the	placebo	group.3	
Another	30-week	study	enrolled	patients	who	were	already	
taking	metformin	and	the	maximum	dose	of	a	sulfonylurea.	
There	were	247	patients	who	injected	a	placebo	twice	daily,	
245	who	injected	exenatide	5	microgram	and	241	who	injected	
10	microgram.	At	the	end	of	the	study,	HbA1c	had	declined	by	
0.6%	with	exenatide	5	microgram,	0.8%	with	10	microgram	and	
had	increased	with	placebo.4	
Exenatide	has	also	been	studied	in	patients	whose	diabetes	
has	not	been	controlled	by	a	thiazolidinedione	with	or	without	
metformin.	A	group	of	121	patients	injected	exenatide	and	112	
injected	a	placebo	twice	daily.	After	16	weeks	the	HbA1c	had	
decreased	by	0.89%	with	exenatide	10	microgram	and	increased	
by	0.09%	in	the	placebo	group.5	
After	the	placebo-controlled	trials,	668	patients	who	had	taken	
exenatide	continued	using	it	in	open-label	extension	studies.	A	
total	of	314	patients	completed	a	further	52	weeks	of	treatment.	
The	reduction	in	HbA1c	seen	at	the	end	of	the	placebo-
controlled	studies	was	maintained.6
In	the	medium-term	placebo-controlled	studies,	more	patients	
dropped	out	of	the	exenatide	groups	because	of	adverse	
effects.2,3,4,5	In	the	trial	adding	exenatide	to	a	thiazolidinedione,	
16%	of	the	patients	withdrew	because	of	adverse	effects	
compared	with	only	2%	of	the	patients	who	added	a	placebo.5	
A	common	problem	with	exenatide	is	nausea.	It	affects	more	
than	40%	of	patients	some	of	whom	will	vomit.	Diarrhoea	and	
dyspepsia	are	also	more	frequent	than	with	placebo.	There	is	an	
increased	frequency	of	hypoglycaemia	when	exenatide	is	added	
to	regimens	containing	a	sulfonylurea.	The	dose	of	sulfonylurea	
may	need	to	be	reduced.
The	exenatide	molecule	is	not	identical	to	human	GLP-1.	
Some	patients	will	develop	antibodies	against	exenatide.	
Hypersensitivity	reactions	may	occur	and	it	is	possible	that	high	
antibody	titres	could	reduce	the	efficacy	of	exenatide.
During	the	30-week	trials,	patients	randomised	to	take	exenatide	
lost	1–3	kg	in	weight.2,3,4	This	continued	in	the	open-label	
extension	studies.	
Exenatide's	role	in	therapy	is	unclear.	If	optimum	therapy	with	oral	
hypoglycaemic	drugs	does	not	control	a	patient's	type	2	diabetes,	
introducing	insulin	is	the	next	step.	Although	exenatide	appears	
to	have	a	similar	effect	on	HbA1c	to	once-daily	insulin	glargine7	
or	twice-daily	insulin	aspart8	in	open-label	studies,	it	causes	more	
adverse	effects.	In	the	comparison	with	insulin	glargine,	19.4%	of	
the	282	patients	injecting	exenatide	dropped	out,	compared	with	
9.7%	of	the	267	patients	injecting	insulin.7	In	the	comparison	with	
insulin	aspart	the	corresponding	figures	were	21.3%	of	the	253	
patients	injecting	exenatide	and	10.1%	of	the	248	patients	injecting	
insulin.8	Gastrointestinal	adverse	reactions	were	common	with	
exenatide	and	contributed	to	these	withdrawals.
In	Europe	there	is	a	risk	management	plan	to	monitor	for	safety	
concerns	such	as	pancreatitis	and	anti-exenatide	antibodies.	
Long-term	outcomes	with	exenatide	are	currently	unknown.	
As	it	is	relatively	expensive, the	use	of	exenatide	may	be	
limited	to	obese	patients	with	insulin	resistance,	but	this	will	
require	further	study.	At	present,	the	Australian	approval	is	for	
adjunctive	therapy	in	patients	who	are	not	achieving	adequate	
glycaemic	control	with	metformin,	a	sulfonylurea,	or	both.
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Approved	indication:	chronic	hepatitis	B
Australian	Medicines	Handbook	section	5.3
Worldwide,	hepatitis	B	is	the	most	common	form	of	viral	
hepatitis.	Some	people	who	are	infected	develop	chronic	
hepatitis	B	which	may	lead	to	serious	liver	disease	such	as	
cirrhosis	and	hepatocellular	carcinoma.	Chronic	hepatitis	B	
infection	is	usually	diagnosed	by	detecting	viral	antigens	and	
their	corresponding	antibodies,	and	viral	DnA	in	serum.1	
Current	drugs	used	to	treat	chronic	hepatitis	B	include	
interferons	and	nucleotide/nucleoside	analogues	(lamivudine,	
adefovir	and	entecavir).
Telbivudine	is	a	synthetic	thymidine	analogue	which	inhibits	the	
replication	of	hepatitis	B	virus	by	binding	to	its	DnA	polymerase	
and	causing	DnA	chain	termination.	It	is	indicated	for	chronic	
hepatitis	B	(irrespective	of	whether	the	patient	has	the	hepatitis	
B	e	antigen	(HBeAg)	or	not)	in	patients	who	have	compensated	
liver	disease,	evidence	of	viral	replication	and	liver	inflammation	
and	who	have	not	previously	been	treated	with	another	
nucleoside	analogue	such	as	lamivudine.
Following	oral	administration	of	telbivudine	(600	mg),	peak	
plasma	concentrations	occur	within	1–4	hours.	Telbivudine	has	
an	overall	terminal	half-life	of	around	42	hours	and	is	eliminated	
mainly	unchanged	in	urine.	Patients	with	impaired	renal	
function	may	need	a	dose	interval	adjustment.	
In	a	phase	I	placebo-controlled	trial,	the	safety,	antiviral	activity	
and	pharmacokinetics	of	telbivudine	were	assessed	in	43	adults	
with	HBeAg-positive	chronic	hepatitis	B.	Patients	were	given	
one	of	six	different	daily	doses	of	telbivudine	for	four	weeks	
and	were	followed	up	for	12	weeks	after	treatment.	The	antiviral	
activity	of	telbivudine,	measured	by	quantifying	serum	viral	
DnA	(using	the	polymerase	chain	reaction),	appeared	to	be	
higher	at	doses	of	400	mg	or	above.2
A	subsequent	phase	II	trial	compared	the	safety	and	efficacy	of	
telbivudine	(400	or	600	mg/day)	and	lamivudine	(100	mg/day)	
alone	or	in	combination,	in	104	patients	with	HBeAg-positive	
chronic	hepatitis	B.	At	week	52,	there	was	no	detectable	viral	
DnA	in	61%	of	patients	on	telbivudine	monotherapy	compared	
to	32%	of	patients	on	lamivudine	monotherapy	(p<0.05).	
Likewise,	a	greater	proportion	of	patients	taking	telbivudine	
monotherapy	had	improved	liver	function	(normalisation	of	
alanine	transferase)	compared	to	those	taking	lamivudine	
monotherapy	(86%	vs	63%,	p<0.05).	Combination	treatments	
with	telbivudine	were	no	more	effective	than	telbivudine	alone.3
Results	of	a	two-year	multicentre	phase	III	trial	comparing	
telbivudine	(600	mg/day)	and	lamivudine	(100	mg/day)	are	
currently	unpublished.	This	trial	included	approximately	1300	
patients	with	HBeAg-positive	or	-negative	chronic	hepatitis	B.	
Interim	results	suggest	that	viral	suppression	was	greater	in	
patients	treated	with	telbivudine	than	in	those	treated	with	
lamivudine.	Improvements	in	liver	function	were	not	statistically	
different	between	the	two	treatments.	
The	efficacy	of	telbivudine	has	also	been	compared	to	adefovir	
in	an	open-label	trial	of	136	HBeAg-positive	patients.	After	a	year	
of	treatment,	there	seemed	to	be	greater	viral	suppression	with	
telbivudine	than	with	adefovir.4
In	the	phase	II	and	III	trials,	genetic	evidence	of	viral	resistance	
was	found	following	viral	breakthrough	in	some	patients.3	In	
in vitro	studies,	some	viral	strains	that	showed	resistance	to	
other	nucleotide/nucleoside	analogues,	such	as	lamivudine	or	
adefovir,	also	had	reduced	susceptibility	to	telbivudine.	
The	safety	profiles	of	telbivudine	and	lamivudine	were	
comparable	in	the	phase	III	trial,	with	muscle-related	symptoms	
being	the	most	common	treatment-emergent	clinical	adverse	
events,	occurring	in	2%	of	all	patients.	Creatine	kinase	elevations	
occurred	in	9%	of	telbuvidine-treated	patients	and	3%	of	
lamivudine-treated	patients.	
Telbivudine	comes	with	a	warning	about	the	risk	of	myopathy.	
Patients	taking	telbivudine	should	therefore	be	advised	to	report	
any	unexplained	muscle	aches,	pain,	tenderness	or	weakness.	
Treatment	should	be	stopped	if	myopathy	is	diagnosed.	
Health	professionals	should	also	be	aware	that	discontinuing	
telbivudine	treatment	may	lead	to	severe	acute	exacerbations	of	
hepatitis	B	infection.	Hepatic	function	should	be	monitored	for	
a	minimum	of	several	months	once	therapy	has	been	stopped.	
When	monitoring	hepatic	function	in	patients	taking	telbivudine,	
check	for	flares	in	alanine	transferase.	
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Answers to self-test questions
1.	 False
2.	 False
3.	 False
4.	 True
*	 At	the	time	the	comment	was	prepared,	information	about	
this	drug	was	available	on	the	website	of	the	Food	and	Drug	
Administration	in	the	USA	(www.fda.gov).
†	 At	the	time	the	comment	was	prepared,	a	scientific	
discussion	about	this	drug	was	available	on	the	website	of	
the	European	Medicines	Agency	(www.emea.eu).
TThe	T-score	(					)	is	explained	in	'Two-way	transparency',	Vol	28	
no	4,	2005	(Aust	Prescr	2005;28:103).
T
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Telbivudine	offers	a	new	therapy	for	patients	diagnosed	with	
chronic	hepatitis	B	infection.	While	telbivudine	seems	to	
be	effective	at	reducing	viral	loads,	we	do	not	know	if	viral	
resistance	will	become	a	problem.	It	is	not	known	if	this	drug	
will	reduce	the	long-term	complications	associated	with	chronic	
hepatitis	B.
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